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Abstract
Glycoside hydrolases are ubiquitous and one of the most catalytically proficient enzymes
known, and thus understanding their mechanisms are crucial. Most research has focused on the
interaction of the glycon of substrates and their inhibitors within the active site of glycoside
hydrolases. The inhibitors employed to probe these interactions generally had small aglycons
(i.e. a hydrogen atom, amidines, small aliphatic groups, or benzyl groups). Here, the interactions
of the aglycon with glycoside hydrolases are examined by probing the active sites with a library
of 25 galactonoamidines. The studies described in this dissertation aim to increase the
understanding of stabilization of the transition state by glycoside hydrolases, which allows for
the acceleration of substrate hydrolysis by the enzymes up to 1017 over non-enzymatic
hydrolysis. To understand this stabilization, the active sites of -galactosidases from Aspergillus
oryzae, bovine liver, and Escherichia coli were evaluated using spectroscopic, molecular
docking, and modeling analyses to determine transition state analogs (TSAs) and how the TSAs
interact within the active site of glycoside hydrolases.
The probing with the galactonoamidine library revealed hydrophobic interactions, -
interactions, and CH- interactions within the active sites to varying extent. Further, three TSAs
were found for the hydrolysis of substrates by -galactosidase (A. oryzae), and two TSAs for the

-galactosidases from bovine liver and E. coli. Upon TSA binding to the three -galactosidases,
conformational changes occurred to stabilize the galactonoamidines within the active sites,
which did not occur when fortuitous binders interacted with the enzyme. The conformational
changes within the active sites of -galactosidases from bovine liver and E. coli closes off the
active site via a loop movement resulting in a substantially higher binding affinity than those
observed with -galactosidase (A. oryzae). A subsequent evaluation of galactonoamidine

specificity in the presence of other proteins revealed an increase of inhibitory activity two orders
of magnitude more than a purified -galactosidase (E. coli).
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Introduction
Carbohydrates account for approximately two-thirds of the carbon atoms on Earth.1

Therefore, reactions with these glycosides must be considered as one of the most important to
occur. Similarly, the enzymes that interact with these carbohydrates must be considered equally
important.2 The carbohydrate processing enzymes have been divided into three classes: glycoside
hydrolases, glycosyl transferases, and polysaccharide phosphorylases.2 Due to the fact that
glycoside hydrolases can accelerate the non-enzymatic hydrolysis of glycosidic bonds by an
astounding 17 orders of magnitude, understanding the mechanisms and stabilization of the
transition states of hydrolysis by the glycoside hydrolases are paramount.3
The first mechanism for their hydrolysis of substrates was proposed by Koshland in 1953
and has not changed much since.4 However, the mechanism does not account for the role of the
aglycon during the reaction. Summarized here is the general mechanism and classification of
glycoside hydrolases, design of azasugars inhibitors, transition state theory and its application to
glycoside hydrolases, and finally the contribution of the Striegler laboratory to the field.

Glycoside Hydrolase in Nature
Glycoside hydrolases (GHs) cleave di-, tri-, oligo-, and polysaccharides, making them
essential in biological processes such as:5 hydrolysis of storage and structural polysaccharides,6
defense against viruses and pathogens,7, 8 and cell surface interactions.9, 10 The fundamental
necessity for the GHs is evident based on all organisms containing genes to code for these
enzymes, with the exception of some Archaeans and some unicellular eukaryotes.3 The GHs
cleave these saccharides with either a retention or inversion of the stereochemistry at the
anomeric carbon atom.2 Koshland proposed that the inverting enzymes cleave the glycosidic
bond in a single step, while the retaining GHs do so through a double-displacement mechanism
1

involving an glycosyl-enzyme intermediate, Figure 1.1.4 Both of these mechanisms have an
oxocarbenium transition state during cleavage of the glycosidic bond, Figure 1.1.11
In the inversion mechanism, a residue acts as a catalytic acid to donate a proton to the
anomeric carbon atom while a different residue acts as catalytic base to remove a proton from a
water molecule, which facilitates a nucleophilic attack on the anomeric center.12 In the doubledisplacement mechanism of the retaining GHs a residue acts as both a general acid and general
base in a two-step process: glycosylation and deglycosylation.2 In the glycosylation step, the
general acid/base facilitates the aglycon to leave by donating a proton to the glycosyl oxygen
atom, while a residue acts as a nucleophile to form a glycosyl-enzyme intermediate.12 In the
deglycosylation step, the general acid/base activates a water molecule, which attacks the covalent
intermediate and facilitates the release of the glycon.12

Figure 1.1 Koshland’s mechanism for inverting and retaining glycoside hydrolases.13

2

A few alternative mechanisms have been proposed over the years.14, 15 In the mechanism
proposed by Phillips protonation of the glycosidic oxygen atom by a general acid/base residue
leads to cleavage of the bond and formation of an oxocarbenium ion.14 The oxocarbenium ion is
stabilized by the negative charge of an Asp residue within the active site until a hydroxyl group
binds to the positively charged anomeric carbon atom and the general acid/base is reprotonated.14 In the mechanism proposed by Post and Karplus, the oxygen atom at position five
of the glycon is protonated, which results in the cleavage of the bond between the anomeric
carbon and this oxygen atom.15 Then, attack by a water molecule, cleavage of the glycosidic
bond and a subsequent ring closure result in the final products.15 Three main differences between
the mechanisms are: (1) the ring opening that occurs with the Post and Karplus mechanism,15 (2)
the Koshland and Phillips mechanisms require catalysis by enthalpic stabilization (distortion of
the glycon),4, 14 whereas the Post-Karplus mechanism catalyzes by entropic contributions
(orientation of the glycon),15 and (3) only the Koshland mechanism has a glycosyl-protein
intermediate.15 The glycosyl protein intermediate and the oxocarbenium transition state of
Koshland’s mechanism have been proven through kinetic isotope studies,16 inhibition with
irreversible fluoro-glycosyl inhibitors,17 and NMR studies.18
In order to differentiate the tremendous number of GHs in nature as retaining or inverting
enzymes as well as specificity, they have been grouped into clans and subdivided into families.19
At first the GHs were classified based off of mechanism (retention or inversion) and then
subdivided based on sequence similarity.20 However, the subdivision based off of sequence alone
was inefficient.5 Therefore, they were examined by hydrophobic cluster analysis, which has a
high reliability with low sequence identity, and has the ability to detect secondary structure based
on an enzyme’s sequence.5 Using the second method, they were classified based on mechanistic

3

similarities, and sequence conversion was focused on the areas surrounding the catalytic
residues.21, 22 This new classification system has classified all GHs into 18 clans (A-R) and 156
families.23 The families have similar substrate specificity, evolutionary relationships, structure,
and of course mechanisms.23 Much that is known about the mechanistic details has been acquired
by using inhibitors to probe the active sites of the enzymes. The probing has helped understand
the importance of conserved residues, whether it is retaining or inverting, and the specificity.

Inhibitors of Glycoside Hydrolases
Glycoside hydrolases have been studied using covalent and noncovalent inhibitors.24 25 24,
26

The covalent inhibitors of glycoside hydrolases usually form a covalent bond when the

catalytic residue that acts as a nucleophile attacks an electrophilic portion of the inhibitor.27
These inhibitors can be categorized as affinity labels or mechanism based inhibitors.25 Two
classes of affinity labels have been employed to investigate the active site of the glycoside
hydrolases: molecules that require stimuli to bind and those that do not.28 Both classes of affinity
labels have been used to label active sites of glycosides.27 Some photoactivated labels employed
are 3,7-Anhydro-2-azi-1,2-dideoxy-D-galactopyranoside (1a) and 4-[azidosalicyl-amido]
butylamido-N-pentyl-1-deoxynojirimycin (1b), with -galactosidase from E. coli and glucosidase from humans respectively, Figure 1.2.29, 30 The inhibitors that do not require
activation have a tendency to spontaneously hydrolyze; however, a few (1c-e) have been used to
examine the active site of retaining -galactosidases, Figure 1.2.31, 32 The main drawback with
these probes is that the aglycons are unspecific in binding.33 Therefore, not all residues labeled
are important in the binding of substrates within the active site.33

4

Figure 1.2 Structure of some covalent inhibitors used to probe glycoside hydrolase active sites.

Mechanism-based inhibitors (MBIs) are substrate analogs that are stable until acted upon
by the enzyme.25 Three main types of MBIs exist for glycoside hydrolases: glycosides with
reactive aglycons, epoxide- and aziridne-based inhibitors, and activated fluorinated glycosides.27
All MBIs with reactive aglycons are derived from difluoroalkyl glucoside (1f), which was the
first developed.34 After cleavage of the glycosidic bond, the aglycon decomposes into a reactive
alkyl fluoride which in turn binds to the protein.34 The enzymatic attack on epoxide and
aziridine-based MBIs (1g) results in labeling of the nucleophile by the glycon of the MBI. Some
of the resulting inhibitor-protein complexes have been characterized by X-ray diffraction,
allowing for determination of nucleophiles of these enzymes.35-37
The final class of MBIs, activated fluorinated glycosides, can also be labeled as slow
enzymatic substrates.38, 39 The glycosyl-enzyme intermediate created during inhibition can be
hydrolyzed, allowing for the rescue of the enzyme activity38. The first fluorinated glycosides, 2deoxy-2-fluoro glycosides (2a-b), were developed by Withers in 1987, Figure 1.3.17 The
5

substitution of the hydroxyl group at C-2 in the glycon slows the formation of the glycosyl
enzyme intermediate and its hydrolysis by destabilization of both transition states.27 The twofold destabilization is attributed to the inductive effects of the addition of the fluorine as well as
the removal of key hydrogen bonding interactions over the hydroxyl group at C-2 in the
glycon.40

Figure 1.3 Structures of activated 2-deoxy-2-fluoro glycosides.

The fluorinated glycosides have been influential in three major mechanistic studies with
glycoside hydrolases. Firstly, the fluorinated glycosides, along with the other MBIs, have helped
identify the catalytic nucleophile in glycoside hydrolases by covalent attachment.41 Secondly, the
fluorinated glycosides were instrumental in solidifying the double-displacement mechanism
proposed by Koshland,4 rather than the ion-pair intermediate mechanism proposed by Phillips,14
as the glycoside hydrolase mechanism.42 Finally, an elegant study conducted by titration of
glycoside hydrolases with 13C labeled catalytic residues in the presence and absence of the
inhibitors exposed the role of the proton donor throughout the reaction.43 Unlike the affinity
labels, the MBIs are specific however, only the interactions of the glycon within the active site
are revealed.
The general trend for design of the noncovalent inhibitors is to synthesize inhibitors that
mimic the transition state of substrate hydrolysis by the GHs.44 The discussion of these
noncovalent inhibitors will be focused on azasugars designed to mimic the transition state (3a-k)
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due to the similarities to the galactonoamidines used in the Striegler laboratory. In efforts to
mimic the oxocarbenium ion-like transition state (TS), the inhibitors are endowed with one or
more of the following characteristics: a flattened half-chair conformation of the glycon due to
sp2-like character at the anomeric carbon atom, a positive charge that is delocalized over the
anomeric carbon atom, and aglycons that mimic the bond lengthening of the glycosidic bond
during the TS.44-47
Though deoxynojirimycin (3a), isofagomine (3b), and azaisofagomine (3c) lack the
flattened chair characteristic most desire, the endocyclic nitrogen atom mimics the charge
desired at the anomeric carbon atom during cleavage.48 In order to incorporate some sp2 nature
into these compounds a similar compound, isofagomine lactam (3d), was synthesized. In
addition to addition of sp2-character, this compound is able to tautomerize to form a hydroxyl
group in at C-2 position of the glycon unlike 3b and 3c, Table 1.1.49, 50 As previously stated, the
hydroxyl group at C-2 of the glycon has been shown to be important in the binding of substrates
and inhibitors to the active sites of glycoside hydrolases.51, 52
The first inhibitors that mimicked the delocalized positive charge and the flattening of the
glycon due to sp2-hybrodization of the anomeric carbon atom were developed by Ganem in the
1990s, 3e-h.45, 53 These inhibitors were established to be broad spectrum inhibitors based on their
ability to inhibit -glucosidase (Almonds; 3g Ki= 8.4M), -mannosidase (jack beans; 3h Ki=
0.17M), -galactosidase (green coffee bean, 3f Ki=8.3M), and -galactosidase (bovine liver,
3f Ki= 6.5M).53 There was initial speculation if these inhibitors were able to be transition state
analogs because of the lack of specificity and the various accounts of the placement of the double
bond.54, 55 However, the glyconoamidines tautomerize and thus the double bond is not fixed as
endo or exocyclic. Further, the pKa of the glyconoamidines is typically between 8-10, and thus
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the amidines are protonated under all conditions discussed here in. Therefore, the inhibitors have
a delocalization of positive charge that would result from either an exo- or endocyclic double
bond.53, 56 Vasella’s imidazole- (3i), triazoles- (3j), and tetrazole-based (3k) azasugars mimic
both the flattened chair and the positive charge of the transition state.57 The Vasella inhibitors
were more effective inhibitors for the -galactosidase (E. coli) than 3a-c, with the inhibitor’s
effectiveness decreasing with increasing number of nitrogen atoms within the cycles, Table 1.1,
(Ki 3i<3j<3k).58, 59 Though these and other inhibitors are designed to mimic the transition state
of the enzymes, relatively few have been experimentally proven to be a transition state analog.
These experiments and the reason for desiring a TSA will be discussed in the following section.

Table 1.1 Inhibition constants (Ki; M) of -galactosidases by azasugars designed to mimic the
transition state of hydrolysis of substrates.
bovine
Compound
Inhibitor
A. oryzae
E. coli
liver
3a

n.d.

1324

12.553

3b

n.d.

0.260

n.d.

3c

n.d.

0.3060

n.d.

3d

0.01861

n.d.

n.d.

3e

n.d.

0.162

10±0.553
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Table 1.1 cont’d Inhibition constants (Ki; M) of -galactosidases by azasugars designed to
mimic the transition state of hydrolysis of substrates.
bovine
Compound
Inhibitor
A. oryzae
E. coli
liver

3f

n.d.

n.d.

6.5±0.153

3g

n.d.

n.d.

19±153

3h

n.d.

n.d.

57±2.553

3i

n.d.

0.00459

n.d.

3j

n.d.

0.259

n.d.

3k

n.d.

1.063

n.d.

Transition states and transition state analogs
During enzymatic reactions, the active sites stabilize the transition state (TS) by
optimization of noncovalent interactions of the substrate to a greater extent than the substrates’
ground state.64 This ability to stabilize the TS reduces the activation energy of the reaction and
thus allows the enzymes to accelerate chemical reactions.65 Using Eyring’s theory of transition
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states, Lienhard and Wolfenden established the thermodynamic relationship between groundstate binding and TS binding for enzymes and their substrates (Figure 1.4).66-68

Figure 1.4 Transition state theory of a non-enzymatic reaction (top) and enzymatic reaction
(bottom).

According to transition state theory, enzymatic catalysis (kE) is faster than non-enzymatic
catalysis (kN) due to the tighter binding of the TS within the active site than the substrate.68 Since
most measured substrate binding affinities (KS) to date are approximately 103-105 M-1, the
binding affinity of the transition state (KT) could potentially reach up to 1015 M-1. 68 The known
binding ratios for transition states and substrates to enzymes (KT/KS) are 108-1014, ideally a TSA
would have a similar binding ratio (KTSA/KS). 68 However, current TSA’s KTSA/KS are quite
lower that this expected ratio, only 102-105.68 The inability of current TSAs to meet the
theoretical enhancement of binding is attributed to the fact that no stable molecule can accurately
mimic the electronic and geometric characteristics of the unstable TS structure.65 This is
especially true for areas at which bond cleavage and/or formation occurs.65
With these general TS and TSA properties in mind, the TSs and TSAs of glycoside
hydrolases can be examined.54, 69, 70 As discussed previously, the current methods of designing
TSA for glycoside hydrolases involve the incorporation of the electronic mimicry by addition of
nitrogen atoms within the heterocycles, and interchanging a glycoside’s normal tetrahedral sp3
anomeric carbon atom for the planar sp2 aromatic carbon atom to mimic the chair flattening
10

during the TS.71 Usually these glycoside hydrolase inhibitors are called TSAs on a conceptual
basis, for having the characteristics of the TS.65 Yet, some well-designed studies have been
developed that distinguish true TSAs from fortuitous binders with the characteristics of a TS.54,
69, 72, 73

Methods by which enzyme TS or its TSA have been examined include kinetic isotope

effects of the substrate,16 QM/MM of substrate itinerary,74 crystallography of enzymes with
TSAs in the active sites,75, 76 mutations of residues within the active sites,77 and spectroscopic
analysis.78 For brevity, only the mutation of active site residues and spectroscopic analysis
methods will be discussed here due to their similarities to methods in later sections.70, 79
Both of these methods take advantage of the thermodynamics of substrate and TSA binding
to enzymes by the free energy relationship that correlates the free energy of activation for
substrate turnover (kcat/KM) with the free energy of inhibitor binding to the enzyme (Ki).78 In
order for an inhibitor to be classified as a TSA, the slope of this free energy relationship plot, as
well as the correlation factor (R2), should be near 1.78 These methods have been employed to test
whether seven inhibitors similar to inhibitors in Error! Reference source not found. were TSAs
of glycoside hydrolases in two studies.54, 69
The first study was conducted by Ermert et al with Vasella’s gluco- (3l) and mannonojiritetrazole (3m), Figure 1.5.54 Here, the ability of 3l and 3m to inhibit the hydrolysis of
model substrates by five enzymes was examined: -mannosidase (jack bean), -mannosidase
(almonds), -mannosidase (snail), -glucosidase (yeast), and -glucosidase (Agrobacter).54 The
inhibition of hydrolysis of both manno- and glucopyranosides with the corresponding inhibitor
was examined spectroscopically with each enzyme.54 A double logarithmic plot of the catalytic
efficacy and inhibition constants of each enzyme with each substrate showed a high linearity
(R2=0.90), but the slope of the line was not 1, rather it was 0.82±0.10.54 Ermert classifies these
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nojiritetrazoles as broad spectrum TSAs of the hydrolysis of glycosides by gluco- and
mannosidases.54 However, we will be more rigorous in our classifications in later chapters, and
not classify any inhibitor as TSA unless the slope of the linear free-energy relationship is
1.00±0.10.

Figure 1.5 Vasella’s gluconojiritetrazole (3l) and mannonojiritetrazole (3m).

The other examinations for TSAs used the mutation method for evaluation of five
inhibitors as TSAs of Cex xylanase, Figure 1.6. All of the inhibitors were able to inhibit Cex
xylanase, an exoglucanase, with inhibition constants between 0.13 and 5.8M.50 Ten mutations
were made to Cex xylanase and the catalytic turnover and binding affinity were determined in
the presence and absence of the five inhibitors.69 All ten of the mutations were made within the
active site of the enzyme: Glu43Ala, Asn44Ala, Lys47Ala, His80Asn, His80Ala, His80Gln,
Gln87Met, Gln87Thr, Asn126Ala, and Asn169Ala.69 In efforts to determine if the sp2hybridization is needed at the anomeric carbon atom, three xylobiose based inhibitors with sp2
hybridization, lactam oxime (3n), imidazole (3o), and isofagomine lactam (3p), were compared
to two inhibitors with sp3-hybridization at the anomeric center: deoxynojirimyxine (3q) and
isofasomine (3r). All of the inhibitors analyzed were charged under the assay conditions.69
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Figure 1.6 Xylobiose based inhibitors of Cex xylanase.

All the inhibitors with sp2 hybridization of the anomeric carbon had slopes similar to one
with the excellent correlations (3n Figure 1.7, 3o, and 3p).69, 80 Based on the criteria set out by
Bartlett and Lienhard, these three inhibitors are TSAs of the Cex xylanase hydrolysis of
substrates.69, 78 The two inhibitors with sp3-hybridization of the anomeric carbon had a slope very
different than one (3q-0.82±0.10) or poor correlation of the free energy plot (3r- R2=0.74),
Figure 1.7.69 The isofagomine-based inhibitor’s low correlation was attributed to the sp3hybridization at the anomeric carbon atom and the missing hydroxyl group at the C-2 of the
gluco-moiety, which is known to be important in binding (See section 1.2 above).17, 69 Up to this
point only gluco- and manno- azasugars had been examined as TSAs, with little to no evaluation
of how the aglycon interacts during substrate hydrolysis. The research presented here is aimed at
filling these gaps.
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Figure 1.7 Free-energy relationship studies of xylobiose based inhibitors 3n (A) and 3r (B) with
Cex xylanase.69

Initial evaluations of galactonoamidines
Most of the azasugars developed have only been able to inhibit glycoside hydrolases in the
micromolar range with few delving into the high nanomolar range.71 Previous endeavors to
increase the binding affinity of these azasugars have been aimed at addition of electrostatic
interactions into the aglycons with and without additional hydrogen bonding groups and addition
of hydrophobic groups to the aglycon.81 The Striegler laboratory endeavored to create
galactonoamidines with the ability to inhibit in the nanomolar concentration range.82 To
accomplish this increase in binding affinity, the above mentioned aliphatic aglycons were
incorporated, as well as lengthening of the distance between the glycon and aglycon by addition
of a methylene spacer, Figure 1.8A.82 The seven synthesized N-benzyl galactonoamidines (4a-g)
were first evaluated in their inhibition ability of -galactosidase (A. oryzae).82
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Figure 1.8 (A) Initial seven galactonoamidines synthesized to inhibit hydrolysis of substrate by
-galactosidases.82 (B) Lineweaver-Burk plot with 5h as a model substrate showing competitive
inhibition of -galactosidase (A. oryzae) in the absence of inhibitor (cyan), 0.2M 4b (navy), and
0.5M 4b (blue).82

The N-benzyl galactonoamidines were able to competitively inhibit the hydrolysis of
galactopyranosides by -galactosidase (A. oryzae) in the low nanomolar concentration range (1248nM), Figure 1.8B.82 The low nanomolar inhibition pointed towards the inhibitors being TSA.
No other galacto- azasugar had previously been examined as a TSA.83 Rather than performing
mutations and having to express and purify multiple proteins, a different method for TSA
analysis was employed.83 The analysis consisted of an examination of the hydrolysis of ten
structurally related substrates (Figure 1.9) through a method developed by Bartlett et al.78 The
binding energy of the TS is compared to the binding energy of the inhibitor similarly to the
previously discussed evaluations.78 However, prior to this work, only two galactopyranoside
substrates were commercially available, 5a and 5h Therefore, substrates 5b-g and 5i-j were
synthesized by modification of procedures for related compounds developed by Thiem et al. 70 84
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Figure 1.9 Aryl--D-galactopyranosides 5a-j developed as model substrates for -galactosidase
(A. oryzae) in evaluation of N-benzylgalactonoamidines as TSAs.83

The initial study of the seven aryl-D-galactonoamidines as a TSA identified a single
putative TSA, 4b,85 Figure 1.10.70 The binding of the N-substituted galactonoamidines is
strongly affected by stereoelectronic effects at the para position of the aromatic ring, observed in
the comparison of 4b and 4e.70 The stereoelectronic effect influences the strength of the
inhibitor, as well as its ability to successfully function as a TSA.83 The ability of one (4b) of the
seven to effectively mimic the TS of the hydrolysis led to the conclusion that the aglycon plays a
significant role in the binding of the inhibitor within the active site.83
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Figure 1.10 Correlation of the binding energy of inhibitor (logKi), 4a (navy)and 4b (orange) to
binding energy at the transition state (-logkcat/KM) of the hydrolysis of ten galactopyranoside
substrates by -galactosidase (A. oryzae).83

The observed importance of the galactonoamidines’ aglycon prompted a more in-depth
investigation of interactions occurring between the aglycon and the active site of -galactosidase.
Probing of the active site was accomplished with a library of 20 galactonoamidines.86 The library
was designed to initiate various interactions including: - stacking, steric, electronic,
hydrophobic, van der Waals interactions, and spacing effects, Table 1.2.86 The binding affinities
of the galactonoamidine library to the -galactosidase were some of the highest observed prior to
this study (6.3-602nM).86 The structure activity relationship study showed that the galactosidase (A. oryzae) was significantly more inhibited with the addition of the methylene
spacer to the aglycon as expected due to the bond lengthening during hydrolysis of substrates (Ki
4r and 4t << 4p and 4s).86 The study also showed that hydrophobic interactions with the aglycon
were more favorable than - interactions (Ki 4s < 4a).86 These new inhibitors’ high binding
affinities and diversity make them excellent probes not only for the interactions occurring within
the active site of the -galactosidase (A. oryzae), but a host of other glycoside hydrolases.
Probing of active sites with these galactonoamidines will lead to increased understanding of the
17

transition states of the enzymes and interactions that occur to promote the stability of the
transition state within the enzyme, allowing for accelerated reactions.
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Table 1.2 Inhibition of hydrolysis of 2-chloro-4-nitrophenyl--D-galactopyranoside (kcat= 2381±135min-1and KM= 0.70±0.1mM) by
-galactosidase (A. oryzae) in the presence of galactonoamidines. 50mM Acetate buffer solution at pH 5.00±0.05 and 30.0±0.1°C.67
Ki [nM]66

Compound

4a

21.1±1.2

4k

149±2

4b

8.0±0.5

4l

10.8±0.7

4c

29.4±5.2

4m

48.4±3.3

4d

23.6±2.4

4n

7.8±1.4

4e

10.1±2.5

4o

8.6±1.2

4f

20.3±2.3

4p

31.9±1.8

4g

16.1±0.3

4q

602±52

Compound

Aglycon

Aglycon

Ki [nM]66
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Table 1.2 cont’d: Inhibition of hydrolysis of 2-chloro-4-nitrophenyl--D-galactopyranoside (kcat=
2381±135min-1and KM= 0.70±0.1mM) by -galactosidase (A. oryzae) in the presence of galactonoamidines.
50mM Acetate buffer solution at pH 5.00±0.05 and 30.0±0.1°C.67
Compound
Aglycon
Ki [nM]66
Compound
Aglycon
Ki [nM]66
4h

20.6±2.5

4r

9.5±1.1

4i

17.1±3.4

4s

11.3±0.9

4j

15.7±0.1

4t

6.3±0.6
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Examination of galactonoamidines with hydrophobic aglycons as putative TSAs for galactosidase (A. oryzae)
Introduction:
Evaluations of the transition state are difficult due to its fleeting nature. Thus, transition

state analogs (TSAs) are designed to probe the active sites of enzymes in an effort to learn about
the transition state.87 During the transition state of glycoside hydrolysis, the substrate’s aglycon
interacts differently than its ground state.68, 69 The aglycon orientation and interactions during the
transition state requires that bond lengthening be incorporated into a good inhibitor.88, 89 Other
interactions that occur with the aglycon of the substrates during transition state have not been
examined as in depth as the interaction of the glycons. Prior to the previously discussed
evaluation of the seven N-benzyl galactonoamidines no TSAs for a -galactosidase were
known.70 The subsequent structure activity relationship (SAR) study using the library of
galactonoamidines (4a-t) revealed that hydrophobic interactions with the aglycon of inhibitors
were the most stabilizing interaction in the active site of -galactosidase (A. oryzae).90
In the SAR study, six galactonoamidines were determined to have IC50 and inhibition
constants (Ki) similar to 4b (Ki=6-11nM and IC50=12-36nM).86 These six galactonoamidines had
aglycons with a linear aliphatic heptyl chain (4l), a branched aliphatic 2-ethylhexyl group (4n),
aromatic substituents with extended spacers (4o), cyclopropyl (4r), cyclohexyl (4s) and
cycloheptyl groups (4t).79 Here, we examine these six inhibitors,
Figure 2.1, through linear free energy relationship analysis to determine TSA,70, 79 docking
analysis,79 and molecular modeling.79
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Figure 2.1 Galactonoamidines selected for TSA analysis.79

Results and Discussion:
2.2.1 Docking analysis of galactonoamidines.
Although all of the galactonoamidines are competitive binders of -galactosidase (A.
oryzae),82 the interactions occurring within the active site had not been established.90 Docking
analysis with AutoDock Vina was employed to determine the binding of the seven
galactonoamidines using the crystal structure available through the protein data bank (4IUG).91 It
was speculated that galactonoamidines bound in a similar manner to 4b will also be a TSA.79
Therefore, the binding of galactonoamidines (4l-o, and 4r-s) were compared to the binding of
4b.79
All of the inhibitors’ glycons bound within the active site in a similar manner (deviation of
> 0.5Å for all non-hydrogen atoms in the glycon), Table 7.1; however, deviations were seen in
the aglycon position within the active site.79 Two inhibitors, 4o and 4s, had very little deviation
from 4b’s position within the active site (less than 30º rotation of the aglycon), Figure 2.2A and
B.79 Inhibitors 4n, 4r, and 4t showed greater deviation of the aglycon position from that of 4b
(82º, 76 º, and 115º respectively), Figure 2.2C-E.79 The final inhibitor 4l showed the most
deviation from 4b (120º) and thus was excluded from further study Figure 2.2F.79
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Figure 2.2 Galactonoamidines (4l-o, 4r-t) docked within the active site of -galactosidase (A.
oryzae) with the catalytically active residues shown in green. The galactonoamidines are overlaid
with the know TSA (4b): (A) 4o (red), (B) 4s (purple), 4t (grey), 4r (pink), 4n (olive), and 4l
(blue).79

2.2.2 Linear Free Energy Relationship Analysis
The five remaining galactonoamidines (4n-o, 4r-t) were then examined as TSAs by
employing the linear free energy relationship method developed by Bartlett.78 In short, the
hydrolysis of a library of substrates (5a-j, Table 2.1) in the presence and absence of inhibitors is
observed spectroscopically.70 The inhibition constants of each inhibitor with the nine substrates
were determined by the average of independent experiments with at least three concentrations of
inhibitor ranging from 0.25-1M, Table 2.1.79 Then, the relationship of inhibition constant (Ki)
23

to the catalytic efficacy (kcat/KM) is determined.79 For the inhibitor to be a TSA, the slope of the
linear free energy relationship and the correlation factor of the line must be near to 1.78 Any
deviation from this criteria shows that the inhibitor is not a TSA, rather just an opportunistic
binder within the active site of the -galactosidase (A. oryzae).79
Table 2.1 Model Substrates for TSA analysis with -galactosidases.79

The galactonoamidines were all able to inhibit the hydrolysis of the model substrates with
nanomolar inhibition constants (6-170nM), Table 2.2.79 However, only two of the five
galactonoamidines (4o and 4s) have a correlation of the inhibition constants to the catalytic
efficiency near 1, along with a R2 near 1(Figure 2.3A).79The slope of the free energy relationship
of the galactonoamidines with the branched linear aglycon (4n) and cycloheptyl aglycons (4t)
were within error of 1; however, the correlation factor for the fit these data is very poor (0.83 and
0.69 respectively), Figure 2.3.79 The correlation of the data obtained for 4r resulted in scattered
data (R2=0.46) and a slope very different than 1.79
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Table 2.2 Galactonoamidine inhibition of hydrolysis of 9 nitrophenyl-β-D-galactopyranosides by
-galactosidase (A. oryzae); 50 mM acetate buffer solution at pH 5.00  0.05 and 30.0  0.1
C.79
kcat/KM x
106 [min1
][M-1]92

Ki [nM]

Ki [nM]

Ki [nM]

Ki [nM]

Ki [nM]

4n

4o

4r

4s

4t

5a

3.61

28.6±0.5

17.4±0.6

35.8±2.7

24.2±1.2

30.4±2.3

5b

3.23

20.8±5.3

11.1±0.1

37.9±2.0

20.3±1.3

42.8±0.9

5c

3.76

31.9±0.8

13.5±0.1

29.7±1.4

20.5±0.1

13.3±3.3

5d

4.31

26.5±0.6

11.8±0.1

14.6±0.1

20.1±4.5

39.2±3.2

5f

2.18

81.5±2.8

21.2±1.8

30.6±0.4

35.5±1.1

135±12

5g

9.86

145±0.7

60.7±2.0

64.9±1.6

87.5±3.2

168±1.9

5h

3.85

40.2±1.4

15.7±1.4

35.2±0.6

16.2±0.1

61.8±2.6

5i

3.99

36.7±0.2

14.2±2.3

51.5±4.0

18.7±1.5

40.6±1.0

5j

3.5986

7.8±1.486

8.6±1.286

9.5±1.186

11.3±0.986

6.3±0.686

S

These spectroscopic evaluations revealed only two galactonoamidines (4o and 4s) met the
criteria to be TSA.79 The two new TSAs (4o and 4s) had the least deviation from the binding
orientation of previously determined TSA (4b) in the molecular docking studies (section 2.2.1).79
These three inhibitors (4b, 4o, and 4s) are in better orientation to interact with residues that form
a tunnel-like hydrophobic region at the rim of the active site than the other inhibitors (4n, 4r, and
4t).79 In order to understand why only two of the five inhibitors were TSA, the protein-inhibitor
complexes were examined by molecular dynamics.79
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Figure 2.3 Double-logarithmic correlation of catalytic efficiency (kcat/KM) and the inhibition
constant (Ki) with linear fit y = ax + b for the 9 nitrophenyl--D-galactopyranosides in the
presence of (A); (4o) (red triangle) a = 1.02 ± 0.10, R2 = 0.93; (4s) (purple pentagon) a = 1.08 ±
0.10, R2 = 0.95; and (B) (4n) (green diamond) a = 1.16 ± 0.21, R2 = 0.83; (4r) (pink hexagon) a
= 0.44 ± 0.19, R2 = 0.46; (4t) (grey pentagon) a = 1.17 ± 0.32, R2 = 0.69.79

2.2.3 Molecular dynamic evaluation of galactonoamidine-protein complexes
Complexes of galactonoamidines and -galactosidase from A. oryzae (PDB ID 4IUG) were
built from the lowest energy conformation determined by AutoDock Vina using the GROMOS
96-43A1 model in GROMACS.79, 91 The hydrogen bonding interactions of the glycon and
interactions of the aglycon and the surrounding residues were evaluated over 30 ns of molecular
dynamics.79 First, the hydrogen bonding interactions of the inhibitors with all residues within the
active site were examined, Figure 2.4A.79 This showed that 4r and 4t had the least number of
hydrogen bonds to residues within the active site.79 The field was then narrowed to the two
catalytic residues, Glu200 (proton donor) and Glu298 (nucleophile).79 All galactonoamidines
showed high occurrence of hydrogen bonding interactions with the nucleophile.79 However, 4n
and 4r showed very little interaction with the proton donor, Figure 2.4B.79 This observation is
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similar to previous indications that suggested the need of an inhibitor to interact with both
catalytic residues to be considered a TSA.93 The orientation of the 4b, 4o, and 4s remained near
identical throughout the simulation (RMSD ≤ 0.65Å), while the galactonoamidines that were not
TSA (4n, 4r, and 4t) were much different (RMSD ≤ 2.26Å).79 The similar orientations and high
probability of hydrogen bonding interactions with catalytic residues reveal that the TSAs are
stabilized differently in the active site than the non-TSAs.79
A
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Figure 2.4 (A) Frequency of hydrogen bonding interactions in correlation to the number of
hydrogen bonding of galactonoamidines with -galactosidase (A. oryzae). (B) Occupancy of the
catalytic residues throughout the 30ns simulations with galactonoamidines.79

After the glycon interactions were examined, focus shifted to establishing what interactions
were occurring with the aglycon throughout the simulations.79 Along these lines, special
attention was paid to the interactions with the hydrophobic residues surrounding the active site
(Ala237, Pro261, Lue262, Phe264, Phe278, Phe281, Ala301, Ala303, Phe304, Ala317, Val391,
Met343, and Trp806).79 These hydrophobic residues make up a hydrophobic tunnel leading
towards the active site.79 The p-methyl substituent of the aglycon of 4b is oriented towards
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Ala237, Pro261, Lue262, Phe264, Pro278 and Phe281 within acceptable distance for
hydrophobic interactions.79 The propylene spacer of 4o’s aglycon allows for interactions with the
same residues as well as Ala301, Ala303, Phe304, Ala317, Val319, Met343, and Trp806.79 The
ability of the three TSAs to interact with these hydrophobic residues is due to small
conformational changes in the loops surrounding the active site that orient the residues in a way
that promotes interaction with the aglycons. These orientation shifts of the hydrophobic tunnel
are also seen in 4s.79 The rearrangement of the hydrophobic residues surrounding the aglycons of
the TSAs result in an overall conformational change of the active site of -galactosidase (A.
oryzae) which stabilizes the TSAs within the active site.79 This change in active site
conformation is not observed in molecular dynamics with an unbound -galactosidase (A.
oryzae), nor when bound to the opportunistic binders (4n, 4r, and 4t), Figure 2.5.79

Figure 2.5 Overlay of the molecular dynamics simulations of -galactosidase from A. oryzea
(dark grey) with 4b (orange) and -galactosidase from A. oryzea (blue) with 4t (cyan). Catalytic
residues are shown as ball and stick (red).79
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Conclusion
Galactonoamidines 4b, 4o, and 4s have been spectroscopically determined to be TSAs and
show similar interactions through docking and molecular dynamics simulations that account for
their ability to accurately mimic the transition state.79 The TSAs’ glycons and aglycons interact
within the active site with similar orientation, whereas galactonoamidines 4n, 4r, and 4t are not
in the same orientation within the active site, Figure 2.5.79 The strong interactions with the
catalytic residues, as well as a conformational change when binding to a TSAs 4b, 4o, and 4s,
allow for sustained interactions with the hydrophobic tunnel surrounding the active site.79 In
contrast, galactonoamidines 4n, 4r, and 4t lack interaction with the catalytic residues and the
conformation change upon binding.79 This difference in binding interactions and orientation
differences account for these three inhibitors being classified as opportunistic binders within the
active site of -galactosidase (A. oryzae) and not true TSA.79

Materials and Methods
2.4.1 Instrumentation
UV/Vis data were collected on a FilterMax F5 Multi-Mode Microplate Reader from
Molecular Devices using a 96-well medium-binding microlon ELISA-plate from Greiner Bioone.79 A Φ 250 pH meter (Beckman) with a refillable ROSS combination pH electrode (Orion)
with an epoxy body and an 8mm semi-micro tip. Prior to each use, the pH meter was calibrated
using standard buffers (4.00, 7.00, and 10.01) purchased from VWR.79 All water used was
Nanopure water at a resistance of 18.2 MΩcm was obtained from a ThermoScientific Barnstead
E-pureTM purification system.79 All compounds were weighed on either an AB135-S Classic
Balance (Mettler Toledo) or a M-120 Balance (Denver Scientific). All molecular dynamics
simulations were performed in the Arkansas High-Performance Computation Center.79
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2.4.2 Materials
Acetic acid (99.7% purity) was purchased from VWR. Sodium hydroxide (99.999% purity)
and -galactosidase (A. oryzae) were obtained from Sigma-Aldrich.82 The -galactosidase was
received as a lyophilized powder, which was stabilized with dextran, and stored at -18ºC until
use. 82 The protein content was previously determined to be 10%.82 The molecular weight was
determined to be 86,800 g/mol-1 by microchip electrophoresis. 82 The synthesis of the
galactonoamidine inhibitors and nitrophenyl -D-galactopyranoside substrates were described
previously. 94, 95 Gibson P-200, P-1000, and SL10 pipettes or a multichannel FinnPipette F2
(Thermo Scientific) were used to for dilutions and addition of compounds into 96-Well plates.
All solutions were prepared using 5mL, 10mL, 20mL, or 500mL volumetric flasks (Duran).
2.4.3 Spectroscopic Evaluation of galactonoamidines
2.4.3.1 Acetate Buffer solution
A 500mL aliquot of 50mM Acetate buffer solution was prepared at ambient temperature
for use at 30°C by standard methods. The buffer solution was stored at ambient temperature and
discarded if not used within 10 days.79
2.4.3.2 Stock solutions of -galactosidase (A. oryzae)
A typical stock solution was prepared by dissolving 4.5 mg of lyophilized -galactosidase
from A. oryzae in 5mL of the buffer solution.79 A 518nM enzyme stock solution was obtained by
dilution of a 500L aliquot to 10mL of buffer solution in a volumetric flask.79
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2.4.3.3 Stock solutions of galactonoamidine inhibitors
Typically, a 1.0mM stock solution of galactonoamidine inhibitor was serially diluted to
0.25, 0.50, 0.75, and 1.0mM with nanopure water in 5mL volumetric flasks.79 The four stock
solutions were kept at ambient temperature until use.79
2.4.3.4 Sock solutions of nitrophenyl -D- galactopyranosides:
A typical stock solution was prepared by dissolving 7-11mg of a nitrophenyl -Dgalactopyranoside (5a-d and 5f-j) in 5mL of acetate buffer solution.79 These solutions were used
within four hours of preparation and kept at ambient temperature.79
2.4.3.5 Kinetic assay
A 0-70L aliquot of the substrate stock solution was added in increasing 10L increments
in a 96-well plate.79 Stock solutions of inhibitor were added in constant 10L aliquots and the
appropriate amount of buffer solution was then added to maintain 80L in each well.79 The plate
solutions were equilibrated to 30°C then a 20L aliquot of the stock solution of enzyme was
added to the wells.79 The product formation was observed at a wavelength of 405nm by change
in absorbance over 15min in 27s intervals, for a total of 34 cycles.79
2.4.3.6 Data Analysis
The formation of product, nitrophenylate, was determined by absorbance at a wavelength of
405nm using previously determined apparent extinction coefficients.83 A linear regression of the
change in product concentration overtime gave the initial rate of hydrolysis.79 These data were
then corrected for enzyme concentration by dividing by the concentration of enzyme in the well,
then the data were averaged for the triplicated samples.79 This average product formation per
minute was then plotted as a function of substrate concentration.79 A non-linear regression fitting
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was performed to determine the catalytic activity and apparent catalytic activity (kcat and kcat’) and
the Michaelis constant and apparent Michaelis constant (Km and Km’). The inhibition constant (Ki)
was determined by the following equation:79
𝐾𝑖 =

[𝐼]𝐾𝑚
′ −𝐾
𝐾𝑚
𝑚

Eq 1

All kinetic parameters were determined in triplicate. The inhibition constants were determined
by averaging the data obtained by 3-4 different inhibitor concentrations.79
2.4.4 Docking Analysis
The PDB coordinates of -galactosidase (A. oryzae) were obtained from the Protein Data
Bank (PDB ID 4IUG).96 All water and solvent molecules and substrates were removed from the
structure. The pdb coordinate file was converted to pdbqt files using PMV-1.5.6 software. 97
Using AutoDock Vina Tools, Kollman partial charges were added to all atoms and all polar
hydrogens added to all residues. 98 Structures of galactonoamidines were energy minimized
using MM2 force field and converted to a pdb coordinate file using PYMOL.79 The coordinate
files were converted to pdbqt coordinate files with all non-ring bonds rotatable.79 A 30x30x30 Å3
grid box was centered in the active site of the -galactosidase.79 All parameters for docking
analysis were set to default of AutoDock Vina 1.1.2 Software with the exception of
exhaustiveness, which was set to 100.79 The software yielded nine inhibitor conformations that
were ranked based on the binding score in kcal/mol.79 The inhibitor conformation with the
lowest binding score was used as an enzyme-inhibitor complex and analyzed for hydrogen
bonding interactions.79
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2.4.5 Molecular dynamics analysis:
All molecular dynamic simulations of galactonoamidines and -galactosidase (A. oryzae)
assemblies were carried out with GROMACS 4.6.7 software employing the GROMOS96 43A1
force field. 99 The pdb coordinate file of -galactosidase (A. oryzae) prepared in docking section
was converted to a GROMACS coordinate and topology file using pdb2gmx program. 100 The
pdb coordinate file of the lowest energy conformation of each galactonoamidine from docking,
were imported into PRODRG, a free software.101 Topology and coordinate files were generated
by maintaining chirality and defining partial charges on all atoms of the galactonoamidine as
GROMOS96 43a1 force field. 101, 102 The energy minimization function was not employed to
keep the lowest energy conformation determined by docking analysis.79 The galactonoamidine
topology file was corrected for partial charge on all atoms within the galactonoamidines and all
charge groups were reduced atoms to 3-4 atoms per group.79 The corrections were accomplished
with guidance from a study conducted Lemkul et al.103
A protein-inhibitor complex was created by appending the edited topology and the
coordinates files of the galactonoamidine to the coordinate and topology files of the galactosidase.79 This protein-inhibitor complex was then centered in a 2389.39nm3 cubic box and
solvated with 75,211-75,214 water molecules using the simple point charge model (SPC). 104
Next, the system was neutralized by replacing random water molecules with 28 sodium cations.79
Systems were then equilibrated to less than 1000kJ/mol using the steepest-decent method. An
NVT simulation using a stochastic scaling thermostat was conducted over 100ps at experimental
conditions of 303K. This was followed by a NPT simulation at 1 bar over 500ps. 105 A 1ns
stability NPT simulation was performed on the system followed by a 30ns NPT. The last 30ns of
NPT were treated as the production.79
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The following constraints were placed on the system during production which allowed for
an integration time step of 2fs:79 Coulomb interactions were calculated to 12Å of each atom,106
outside of this distance a particle-mesh Ewald summation was employed with a spacing of 13Å
and a fourth-order-B-spline interpolation,107 a Verlet scheme was used to cut off London-Jones
interactions,108 and LINCS was used to constrain bond lengths.109 The temperature was
maintained using Nosé-Hoover coupling with a time constant of 2ps and the pressure was
maintained with a Parrinello-Rahman coupling with a time constant of 5ps.110 111 The H-bond
plugin in the Visual Molecular Dynamics (VMD) was implemented to determine the number of
hydrogen bonds with a donor-acceptor cut-off distance of 3.0Å and a donor-H atom-acceptor
20º.79, 112
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3

Exploration of the active site of -galactosidase (bovine liver) reveals loop closure over
active site
Introduction
Glycoside hydrolases (GH) have been categorized into multiple families based on their

mechanism, evolutionary relationship, structure, and sequence.19 These similarities in the
enzymes’ active sites led to speculation that multiple glycoside hydrolases will stabilize their
transition states with similar interactions. 90 Since examining the transition state itself is not
within reason, the interactions with a transition state analog (TSA) and residues within the active
site are examined instead. 90 Along these lines, examination of another -galactosidase from the
same family as -galactosidase (A. oryzae) was desired.90 Two potential enzymes from GH
family 35 were -galactosidase from humans and -galactosidase from bovine liver.19, 23 The galactosidase from bovine liver was determined to be the best candidate to examine the
interactions because of its commercial availability, previous studies with similar inhibitors by
others,44, 71 and similarities within the active site to the -galactosidase (A. oryzae), Figure 3.1.90
Proton Donor
A. oryzae
GGPYILYQPENEYAHAMGN
Bovine Liver GGPIITVQVENEYGSYLSC
*** * * ****
Nucleophile
A. oryzae
STPYSLLEFGAGAFD
Bovine Liver TGPLVNSEFYTGWLD
**
*
*
Hydrophilic Residues
Acidic Residues
Hydrophobic Residues
Basic Residues

Figure 3.1 Sequence similarities of -galactosidases from A. oryzae and bovine liver
surrounding the two catalytically active residues.113

Though the crystal structure for the -galactosidase (bovine liver) is currently unknown,90
previous inhibition studies led to speculation that the binding domain has a separate binding area
35

for the glycon and aglycon, Figure 3.2.53 Based on this speculation, the active site will be
examined with the previously discussed galactonoamidines, three derivatives of a TSA, and two
similar inhibitors lacking an aglycon. Spectroscopic evaluations and homology templating have
been previously used to explore active sites of enzymes that lack a crystal structure.114-117
Though predicting a model for an enzyme by homology templating is a difficult task, multiple
state-of-the-art programs for calculating models and ensuring the model is accurate and of high
quality are available.118-123 With the software and a library of 25 galactonoamidines and their
derivatives on hand, we set out to explore the active site of -galactosidase (bovine liver) using
Michaelis-Menten kinetics,86 transition state analog (TSA) studies,70 and molecular dynamics.90
The spectroscopic evaluations showed drastic differences in binding affinities compared to those
observed with -galactosidase (A. oryzae), which are attributed to a loop closure over the active
site of -galactosidase (bovine liver).90

Figure 3.2 Predicted active site of -galactosidase from bovine liver.124
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Results and Discussion
3.2.1 Spectroscopic evaluations
Initially, a structure activity relationship (SAR) study was performed with the various
galactonoamidines previously synthesized along with galactonoamidines with derivatives at the
glycon.56, 86 Kinetic evaluations for the SAR study were performed using the Michaelis-Menten
model for enzyme kinetics in the presence and absence of galactonoamidines (4a-y).86, 90 All
inhibitors were determined to be competitive inhibitors of -galactosidase (bovine liver), Figure
3.3.90 We expected to see similar inhibition constants to those observed in the SAR evaluation of

-galactosidase (A. oryzae) because of the sequence similarities leading to the enzymes being
classified in the same GH family.19 However, the affinities of inhibitors show an astounding
increase of about two orders of magnitude towards the -galactosidase (bovine liver) (0.052.34nM) than those observed with -galactosidase from A. oryzae (Ki= 6.3-604nM), Table
3.1.86, 90 The drastic affinity difference revealed that the -galactosidase (bovine liver) active site
was able to stabilize the galactonoamidines better than the -galactosidase (A. oryzae).90
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Figure 3.3 Lineweaver-Burk plot of the hydrolysis of model substrate by -galactosidase
(bovine liver) in the presence of 0nM (grey triangle), 0.05nM (green triangle) 4b, and 0.1nM
(olive triangle) 4b.90
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Moreover, a clear preference for galactonoamidines with an aglycon promoting -
interactions were observed within the active site of -galactosidase from bovine liver (Ki 4a
0.05nM < 4n 0.18nM).90 Unlike the -galactosidase (A. oryzae),86 the -galactosidase (bovine
liver) bound the 1-,2-, and 3-fluoro-N-benzylgalactonoamidines (4e-g) with far less affinity than
that of the unsubstituted N-benzylgalactonoamdine (4a), with inhibition constants of 0.130.23nM compared to 0.05nM.90 The addition of the electron-withdrawing groups to the benzyl
aglycon in 4e-g reduces the ability of these inhibitors to form - interactions within the active
site and thus results in a lower binding affinity than 4a.90 Though 4s cannot have -
interactions, it still binds with a similar affinity to the N-benzylgalactonoamidines (4a-b); it is
possible that this inhibitor forms a CH- bond with an amino acid within the active site similar to
the suspected - bonds of 4a-b and 4o.90 The size of the inhibitor also seems to be more critical
for binding within the active site of -galactosidase (bovine liver) than -galactosidase (A.
oryzae).86, 90 The inhibitors with small aglycons, 4k and 4p-r, have much weaker binding
affinities than 4a (0.32-2.34nM >0.05nM). This reduction in binding is likely due to a
combination of bad fitting in the “aglycon binding site” and the lack of any - interactions.90
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Table 3.1 Inhibition of hydrolysis of 4-nitrophenyl--D-galactopyranoside (kcat= 4.24±0.26min-1and KM= 0.51±0.01mM) by galactosidase (bovine liver) in the presence of galactonoamidines. 5mM HEPES buffer solution at pH 7.50±0.05 and 30.0±0.1°C.90
Compound

Aglycon

Ki
[nM]

IC50
Compound
[nM]

Aglycon

Ki
[nM]

IC50
[nM]
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4a

0.05±0.01

18.9

4k

0.32±0.02

1030

4b

0.07±0.01

57.6

4l

0.11±0.01

24.1

4c

0.11±0.01

16.2

4m

0.24±0.03

42.7

4d

0.20±0.02

118

4n

0.18±0.02

21.6

4e

0.19±0.02

9.1

4o

0.06±0.01

41.3

4f

0.13±0.02

9.4

4p

0.32±0.02 >1000

4g

0.23±0.01

43.1

4q

2.34±0.30 >1000

Table 3.1 Cont’d: Inhibition of hydrolysis of 4-nitrophenyl--D-galactopyranoside (kcat= 4.24±0.26min-1and KM=
0.51±0.01mM) by -galactosidase (bovine liver) in the presence of galactonoamidines. 5mM HEPES buffer
solution at pH 7.50±0.05 and 30.0±0.1°C.
Ki
IC50
Ki
IC50
Compound
Aglycon
Compound
Aglycon
[nM]
[nM]
[nM]
[nM]
4h

0.11±0.01

412

4r

0.39±0.07 >1000

4i

0.12±0.01

26.2

4s

0.08±0.01

11.6

4j

0.16±0.01

15.2

4t

0.16±0.03

45.4

Table 3.2 Galactonoamidine inhibition of hydrolysis of 8 nitrophenyl--D-galactopyranosides by -galactosidase (Bovine Liver);
5mM HEPES buffer solution at pH 7.50±0.05 and 30.0±0.1°C.
kcat
KM
Ki [pM]
Ki [pM]
Ki [pM]
Ki [pM]
Entry
S
[min-1]
[mM]
4a
4b
4o
4s
1
5a
4.53 ± 0.46
0.55 ± 0.18
70 ± 2
148 ± 2
250 ± 8
378 ± 48
2
5b
5.29 ± 0.20
0.29 ± 0.07
77 ± 8
110 ± 2
198 ± 9
138 ± 11
3
5c
8.43 ± 0.89
0.72 ± 0.24
62 ± 9
143 ± 22
174 ± 4
524 ± 48
4
5d
20.4 ± 1.7
0.39 ± 0.11
8.6 ± 0.3
26 ± 3
49 ± 5
44 ± 3
5
5f
7.07 ± 0.85
1.58 ± 0.41
132 ± 3
424 ± 13
279 ± 13
516 ± 32
6
5h
4.24 ± 0.26
0.51 ± 0.10
46 ± 2
71 ± 6
60 ± 11
81 ± 5
7
5i
6.82 ± 0.38
0.47 ± 0.09
60 ± 7
121 ± 5
357 ± 6
299 ± 32
8
5j
7.27 ± 0.40
0.48 ± 0.10
58 ± 6
78 ± 9
266 ± 42
349 ± 42
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Remarkably, the four inhibitors (4a, 4b, 4o, and 4s) with the lowest Ki and IC50 values (Ki
50-80pM and IC50 18-59nM) were some of those observed to have the lowest binding affinities
with -galactosidase (A. oryzae).86, 90 Of these, three (4b, 4o, and 4s) had previously been
determined to be TSAs of the hydrolysis of galactosides by -galactosidase (A. oryzae).79 Thus,
the four inhibitors were examined as potential TSAs of the hydrolysis of galactosides by galactosidase (bovine liver) using the method developed by Bartlett,78 Table 3.2.
Galactonoamidines 4a and 4b were found to be TSAs, whereas 4o and 4s were determined to be
opportunistic binders, Figure 3.4. These results show the need for - interactions in the active
site with the aglycon of the inhibitors to be classified as a TSA. It is probable that there is a
conserved tryptophan in the “aglycon binding site” similar to those observed in other glycoside
hydrolases.6, 128, 129
B
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log(Ki)
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A
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-3.5
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Figure 3.4 Double-logarithmic correlation of catalytic efficiency (kcat/KM) and the inhibition
constant (Ki) with linear fit y = ax + b for the 8 nitrophenyl--D-galactopyranosides in the
presence of (A) (4a) (navy circle) a = 1.08 ± 0.15, R2 = 0.92; (4b) (orange square) a = 1.06 ±
0.11, R2 = 0.95; and (B) (4o) (red triangle) a = 0.66 ± 0.24, R2 = 0.60; (4s) (purple pentagon) a =
1.07 ± 0.23, R2 = 0.87.

41

After determining that 4b was a TSA, this inhibitor was used as a parent molecule to design
inhibitors with derivatizations at the glycon, Table 3.3.90 Similar inhibitors that lacked aglycons
were also employed to study the effect of the aglycon (4u and 4v).86, 90 Similar studies of the
active site interactions of -galactosidase (E. coli) and glycons of inhibitors have been carried
out with fluorinated substrates and galactonoamidine derivatives by us and others. 52, 125-127, 56 As
previously stated, azasugar inhibitors had been employed to examine the active site of galactosidase (bovine liver).53 One of these inhibitors was 4u, which was synthesized by Ganem
et al. This inhibitor was used as a control for all other inhibition constants; the values determined
here were within error of those found by Ganem.53
Table 3.3 Inhibition of hydrolysis of 4-nitrophenyl--D-galactopyranoside by -galactosidase
(bovine liver) in the presence of galactonoamidines. 5mM HEPES buffer solution at pH
7.50±0.05 and 30.0±0.1°C. R= -CH2-C6H4-CH3.90
Ki
IC50
Compound
Glycon Structure
[nM]
[nM]
4u

2000±200

>50,000

4v

2700±260

8700

4w

0.60±0.07

850

4x

1540220

10,800

4y

83860

9200
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As in the previously discussed fluorinated glycoside experiments, the hydroxyl group at the
C-2 position of the glycon was determined to be the most important in binding of the glycon to
the active site of this glycoside hydrolase.90 The hydroxyl group in this position is an important
hydrogen bond donor and without it 4w and 4x are not as stable within the active site (Ki=
0.06ns and 1540nM respectively).90 The large difference in inhibition observed between 4w and
4y is most likely due to steric effects induced by addition of the methoxy group at C-4 of the
glycon.90 Also notable is the fact that the inhibitors lacking an aglycon (4u and 4v) are less
potent inhibitors than the derivatives of 4b.90 This shows that the aglycon is very important in the
stabilization of the glycon within the active site.90 Molecular dynamics simulations were
employed in order to understand this stabilization and why the galactonoamidines bind to the galactosidase from bovine liver 2 orders of magnitude better than to -galactosidase from A.
oryzae.90
3.2.2 Development of model for -galactosidase (bovine liver)
To examine the differences between bindings of the galactonoamidines in the two galactosidases, a homology model of -galactosidase (bovine liver) was prepared.90 Two
different servers were employed to develop a model structure: the M4T server and the Robetta
server.130,120,119, 131, 132 Both servers selected crystal structures from -galactosidase (human)
(3TDH from M4T and 3WF3 from Robetta).90 The sequences of the -galactosidase (human)
and -galactosidase (bovine liver) show a 82% sequence identity, which makes the match
reliable for simulation screenings.133, 134 The data were obtained on June 23, 2016 from M4T
server and May 30, 2017 from Robetta; therefore, any crystal structures added after this point
have no bearing on the modeled enzyme.90
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Figure 3.5 Models from M4T server (red), and model 1 (cyan), model 2 (green), model 3
(yellow), model 4 (pink), and model 5 (orange) from Robetta server.

The six models were all very similar, with the only differences being at the C-terminal tail
(the last 6 residues, 621-626) and a loop that is distal to the active site made up of residues 500521, Figure 3.5.90 The active sites of the Robetta models were all nearly identical surrounding
the active site, with a maximum root mean square error (RMDE) of 0.13Ǻ within 20 Ǻ of the
active site.90 A comparison of the sequences of -galactosidase (human) and -galactosidase
(bovine liver) using BLAST revealed 518 identical residues and 73 residues determined to be
similar, resulting in a 90.5% sequence similarity.90 To establish the model that was built with the
most reliability and therefore should be used for further analysis the models were ranked based
on statistical analysis using the Quality Model Energy ANalysis (QMEAN) server.90 Each model
was given a QMEAN6 score, which range from a high score of 1 and low score of -1, to ascribe
certainty of the model.121 The M4T server had a much lower QMEAN6 score (-0.37) than all of
the models obtained by Robetta (0.55-0.98).90 Model 1 of Robetta had the highest QMEAN6
score (0.98), and therefore this model was selected for further docking and modeling analyses.90
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3.2.3 Molecular dynamics evaluations of galactonoamidine-enzyme complexes
Six inhibitors were selected for the molecular dynamics studies: the two putative TSAs
discovered (4a and 4b) and the two inhibitors that were determined to be opportunistic binders
(4o and 4s) through spectroscopic evaluation, an similar inhibitor that lacks an aglycon (4u), and
an inhibitor with the aglycon of a TSA but a derivatized glycon (4x).90 Analysis of hydrogen
bonding interactions with the galactonoamidines revealed a similar number of overall hydrogen
bonding interactions with the glycon of the inhibitors, Figure 3.6A.90 As expected, the inhibitors
which are TSAs (4a and 4b) show the highest probability of interaction with both catalytic
residues (Glu187 and Glu267), Figure 3.6B.90 The inhibitor with the cyclohexyl aglycon, 4s,
shows less probability with both catalytic residues, showing the importance of - interactions
with the aglycon in the aglycon binding center of the active site, Figure 3.6B.
Simulations with the glycon derivatives showed greater differences in the hydrogen
bonding interactions of 4x and 4b (Figure 3.6A) leading to a drastic 30,000-fold potency
difference, inhibition constants of 0.05nM and 1,500nM respectively.90 The 2-methoxy
derivative, 4x, was found to rotate so that the methoxy group at C-2 of the glycon is no longer
completely within the active site; and thus, is no longer allows for interactions with both catalytic
residues, Figure 3.6B.90 The inhibitor lacking an aglycon, 4u, has a similar number of overall
hydrogen bonding interactions to 4a and 4b, Figure 3.6A.90 Yet, 4u had about 2x less
interactions with the proton donor than 4a.90 Without an aglycon bound within its pocket in the
active site, 4u cannot interact with the catalytic residues to the extent of 4a.90 This inability to
interact results in the reduction of in binding affinity of 4u compared to 4a (4u Ki= 2,000nM).90
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As previously stated, molecular dynamics simulations of TSAs in complex with galactosidase (A. oryzae) showed an induced fit movement that was not observed when
fortuitous binders were simulated within the active site.79 Astonishingly, not only was an induced
fit to stabilize the active site of -galactosidase (bovine liver) observed, but this induced fit
resulted in a conformational shift that shuts off the active site completely via loop closure upon
binding to a TSA, Figure 3.7.90 The molecular dynamics show the binding of 4a and 4b to the
glycon pocket within the active site of -galactosidase (bovine liver), followed by the binding of
the aglycon in its pocket, resulting in the subsequent loop closure.90 During the conformation
change, interaction of the aglycons with residues at the outside of the active site cause a -CH
interaction between a Tyr484 and Trp272 that results in a loop movement and closure of the
active site, Figure 3.7.90 Simulations with opportunistic binders did not show this loop closure or
any significant loop movement in the active site,90 Figure 8.1 appendix 8.2. The binding of 4u
to the glycon pocket within the active site results in a partial closure of the active site loop.90
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However, binding of both glycon and aglycon to their respective pockets within the active site
are mandatory for full loop closure over the active site.90
A

B

C

Figure 3.7 Snapshots of from the 30ns simulation of the 4b (orange) and -galactosidase (bovine
liver) complex showing the active site (A) before, (B) during, and (C) after the loop closure
event. The catalytic residues are shown in green and TRP272 and TYR484 are shown in
magenta.

Conclusion:
The active site of a second -galactosidase from the glycoside hydrolase family 35 was
evaluated to compare to the efficacy of the -galactosidase (A. oryzae).90 The active sites of the
two -galactosidases should impart similar binding affinities and interactions over the aglycon
given the enzymes are classified into the same family.90 Though the galactonoamidines were
competitive inhibitors of both -galactosidases, the galactonoamidines had a two orders of
magnitude increase in binding towards the -galactosidase (bovine liver) than those observed
with -galactosidase (A. oryzae) resulting in inhibition constants in the picamolar scale.90
Spectroscopic evaluations using a library of galactonoamidines revealed that the galactosidase (bovine liver) active site preferred aglycons with the ability to form -
interactions with residues within the active site.90 Four galactonoamidines (4a, 4b, 4o, and 4s)
exhibited the strongest binding affinities with the -galactosidases from bovine liver.90 Three of
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these inhibitors were previously shown to be TSA of the -galactosidase form A. oryaze (4a, 4b,
and 4s,).79, 90 Yet, only 4a and 4b are TSAs for the hydrolysis of galactosides by -galactosidase
(bovine liver). This difference in TSAs again shows the preference for - interactions over
hydrophobic interactions within the aglycon binding pocket of the -galactosidase (bovine liver).
Exploration of this binding difference by molecular dynamics revealed that when galactosidase (bovine liver) binds to a TSA (4a or 4b), a loop closure is observed that closes off
the active site to further interaction.90 This closure is reminiscent of other loop closures that have
been observed in similar TIM barrel type active sites.135 This loop closure combined with
hydrogen bonding over the glycon and hydrophobic interactions and - interactions with the
aglycon are the source of the drastic variance in potency of the galactonoamidines on the two galactosidases.90

Materials and Methods
3.4.1 Instrumentation
All instrumentation in this chapter was described previously in section 2.4.1.
3.4.2 Materials
All commercially obtained chemicals were reagent-grade or higher and were used as received
unless noted otherwise. The -galactosidase (bovine liver) was obtained through Sigma Aldrich
as a lyophilized powder and stored at -18 ºC until further use.90 Sodium hydroxide at 99.999%
metal-free purity and HEPEs buffer were purchased from Sigma Aldrich and used as received.90
The 5mM HEPES buffer solutions were prepared at ambient temperature with compensation for
the temperature difference in the UV/vis experiments (pH 7.50±0.05 and 30.0±0.1°C).90 Substrates
5a and 5h were purchased from Sigma Aldrich and stored at -8ºC.90 Substrates 5b-g and 5i-k were
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synthesized by previously disclosed methods.136 Synthesis of the galactonoamidine inhibitors (4ag,82 4h-t; 86 4u and 4v137) were synthesized previously by described methods.
3.4.3 Spectroscopic evaluations
3.4.3.1 Stock solution of -galactosidase (bovine liver)
The stock solution of enzyme was prepared by dissolving the lyophilized -galactosidase
from bovine liver in 5mL of 5mM HEPES buffer solution and stored at -80°C in 50L aliquots
until use.90 The concentration of the enzyme stock solution was determined to be 139±6.25M
by BCA assay.90 Prior to IC50 and Ki value determination, an aliquot was thawed.90 The entire
50L aliquot was diluted to 5mL with 5mM HEPES buffer solution and stored on ice until use
for IC50 value determination.90 However, for determination of inhibition constants a 20L aliquot
was diluted to 5mL with 5mM HEPES buffer solution and stored on ice until use.90
3.4.3.2 Stock solution of galactonoamidine inhibitors
Typically, 0.005, 0.05, 0.125, 0.25, 0.5, 2.5, 10, 20, 30, 50 and 100M inhibitor solutions
were prepared by diluting aliquots of 100M aqueous solution of the galactonoamidines with
nanopure water.90 All resulting inhibitor stock solutions were used in 10L aliquots in IC50 and
Ki assays and kept at ambient temperature until pipetted into plates.90 Stock solutions of
inhibitors in concentrations of 0.05nM and 0.075nM for 4f and 4s, 0.05nM, 0.075nM, and 0.1nM
for 4a, 4b, and 4g, 0.075nM and 0.10nM 4c, and 4e, 4h-j, 4l-m, 4o, and 4t, 0.10nM and
0.125nM for 4n, 0.15nM and 0.17nM for 4d, 0.15nM and 0.20nM for 4k and 4r, 0.2nM and
0.50nM for 4t, 0.5nM and 0.6nM for 4w, 0.5M, 1.25M and 2.5M for 4v, 1.0M and 2.0M
for 4u, 0.25M and 0.5M for 4y, and 0.5 M and 0.1 M for 4x were used in the determination
of Ki values.90
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3.4.3.3 Stock solution of model substrates
Substrate solutions were prepared by dissolving 4.20-7.84mg (0.013-0.025mmol) of
nitrophenyl--D-galactopyranoside (5a-e and 5h-j) in 5mL of 5mM HEPES buffer solution in a
volumetric flask (2.66-4.94mM).90 The substrate solution was prepared immediately before use
and kept at ambient temperature until pipetted into microplates.90
3.4.3.4 Kinetic Assay
The kinetic assay was prepared the same as section 2.4.3.5 with the following changes: The
plate was read at a wavelength of 405nm at 30°C for 45 minutes with data obtained every 27s.90
3.4.3.5 Data Analysis
The formation of nitrophenylate was determined by absorbance at a wavelength of 405nm
using apparent extinction coefficients (see Chapter 8; appendix 2). All kinetic parameters were
determined in at least duplicate and data analysis was carried out as described in section 2.4.3.6.
An average of 2-3 inhibition concentrations were employed to determine the inhibition constants
(Ki).90
3.4.4 Development of -galactosidase (bovine liver) model
3.4.4.1 M4T model
A -galactosidase (bovine liver) model was obtained through the M4T server vers.
4,130,120,131 through the Protein Model Portal.90 The data was obtained from the portal on June 30,
2016; therefore, any crystal structures added after this point have no bearing on the modeled
enzyme. A model was prepared using Multiple Model Mapping and Modeller.138, 139
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3.4.4.2 Robetta model
The FASTA sequence of -galactosidase (bovine liver) was imported from UniProt (ID
Q58D55) into the Robetta server with the signal peptide (residues 1-28) removed from the
sequence.90 A GRINZU method homology templated was used to determine -galactosidase
from human, 3wf3, was the best match for templating the sequence again, with a high confidence
of 96%.90 A structure calculation by homology and de novo calculations returned five punitive
models.90
3.4.4.3 Quality assessment of models
All six models were uploaded as a pdb’s onto the Quality Model Energy ANalysis
(QMEAN) server and analyzed.90 The model with the highest quality score, which was a
QMEAN6 score of 0.98, was selected for further analysis.90
3.4.5 Molecular Dynamics Simulations
The coordinates of the selected model were imported into PMV, where all polar hydrogens
were added to residues and Kollman charges were added to each atom with AutoDock Vina
Tools.98, 140 A 15x15x15Å grid box was centered in the active site of -galactosidase (bovine
liver).90 Galactonoamidine inhibitors were prepared for docking analysis as described in section
2.4.4.90 All parameters in AutoDock Vina were set to default for all calculations.141 The nine
conformations of each inhibitor were visualized with PYMOL and the conformation with the
lowest free energy estimate was exported as a pdb file for further analysis.142
Inhibitor topologies and coordinates, enzyme topologies and coordinates, and inhibitorenzyme complexes were obtained as previously described in section 2.4.5.90 The complexes
were then solvated with 41,945-41,956 single pint charge water molecules in a 1367nm3 cubic
box.90 Then, a random water molecule was replaced by a sodium ion to neutralize the systems.90
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Energy minimization, equilibration, and the production phase were carried out as described in
section 2.4.5. All analysis of production simulations were carried out with Visual Molecular
Dynamics as previously described in section 2.4.5.90 79
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4

Investigation of galactonoamidine inhibition of -galactosidase (E. coli) under isolated and
cell-like conditions.
Introduction
The active site of all glycoside hydrolases from Clan A are within a TIM barrel motif.23

The entrance to the active sites is made up of eight loops connecting the beta strands to the alpha
helices, which are called the beta/alpha loops.143 The catalytic residues are located on the fourth
and seventh beta strands of the TIM barrel.6 In enzymes with similar TIM barrels as the catalytic
core, motion of the beta/alpha loops help to create microenvironments that accelerate catalysis by
closing over the active site when a ligand binds.135, 144, 145 An excellent example of the loops
acting as a gate occurs during the hydrolysis of substrates by -galactosidase from E. coli.146
A loop closure over the active site of -galactosidase (E. coli) occurs during the transition
state of substrate hydrolysis and when a transition state analog (TSA) is bound within the active
site.146 Thus far, only assumed TSAs, galactonolactone (3l) and galactotetrazole (3k), have been
studied within the active site of -galactosidase (E. coli).51, 146, 147 Both of these inhibitors lack
experimental evidence of them being TSA and lack an aglycon. Previous studies have shown that
the aglycon of glycoside hydrolase inhibitors, TSAs in particular, have key roles in stabilization
of the molecule within the active sites.70, 79, 90 Galactonoamidines have been shown to be TSAs
of two other -galactosidases within clan AError! Reference source not found..70, 79 Considering
the similarities in active sites of GHs,13 it is plausible that these galactonoamidines are TSAs of
the -galactosidase (E. coli) as well. Establishing the interactions of a TSA with aglycons
provides a full picture of the interactions occurring with substrates during the hydrolysis by GHs.
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Figure 4.1 Current compounds synthesized to mimic the transition state that have been
crystalized within the active site of -galactosidase (E. coli).146 Galactonoamidines designed to
mimic the transition state of substrate hydrolysis

This enzyme has two binding modes: a “shallow” and a “deep” mode.148 The interactions
that occur in each mode have been established through crystallization and kinetic experiments
with deoxy- and fluoro- analogs of 2, 4-dinitrophenyl galactopyranosides, Error! Reference
source not found.k and 3l.51, 146, 147 During hydrolysis, substrates first bind within the “shallow”
mode of the active site.146 In this position, the glycosidic oxygen atom of the substrate is
positioned over the indole of W999 and the following hydrogen bonding interactions are
observed: Glu461 (C2-OH), Glu537 (C3-OH), water mediated interaction to Asn460 (C3-OH),
Asp201 (C4-OH), Asn604 (C6-OH), and His540 (C6-OH).148, 149 In this position, there is also a
hydrophobic interaction with the C-6 of the glycon and Phe601.148 This residue becomes
important in the binding at the “deep” mode.146 An additional hydrogen bond is observed with
ONPG substrates with His418 through the nitro group.148
A 90° rotation of the substrate and movement 3-4Å deeper into the active side occurs to
transition the substrate into the “deep” mode of the active site.146 When in the “deep” mode of
the active site, galactose stacks with Trp568 and has hydrogen bonding interactions with Glu461
(C1-OH), Glu537 (C2-OH), Asn460 (C2-OH), His391 (C3-OH), Asp201 (C4-OH), Asn604 (C6OH) and His540 (C6-OH).148, 150 The glucose binding site has only been characterized as having
stacking interactions with Trp999.146 After the substrate has moved to the “deep” mode, Phe601
moves to have a cation- interaction with Arg599. As a result, Gly794, Ser796, and Glu797 are
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no longer anchored by interactions with Arg599, and a beta/alpha loop (Gly794-Pro803) moves
to close over the active site.151-153 This loop closure event is instrumental in the enzyme’s
transglycosylation mechanism to produce allolactose for LacZ regulation.76, 154
It is speculated that the galactonoamidines will inhibit -galactosidase (E. coli) with similar
binding affinities, in the low picamolar concentration range, as observed with other galactosidases with loop closures. Summarized here are the evaluations of binding interactions
with galactonoamidines with spectroscopic evaluation, molecular docking, and molecular
modeling, as well as the exploration of binding interactions in the presence of other proteins
and/or cell components (i.e. lipids and organelles).
Results and Discussion
4.2.1 Active site independence and SAR study
The GH-2 -galactosidases, unlike the previously examined GH-35 -galactosidases,82, 90
are homotetramers at catalytic pH (7.50-8.00) and temperature (25-40°C).155 Prior to extensive
SAR studies, the binding of the galactonoamidines needed to be investigated to ensure that they
bound to the active site of the -galactosidase rather than through an allosteric site. The
galactonoamidine inhibitors were determined to be competitive inhibitors of -galactosidase (E.
coli), Figure 4.2A.56 To ensure that the galactonoamidines do not interact with multiple active
sites of the homotetramers, a plot of apparent Michaelis-Menten constant vs inhibitor
concentration was constructed to measure cooperativity, Figure 4.2B.156 The high correlation of
the apparent Michaelis-Menten constant and inhibitor concentration (R2=0.999) revealed that the
active sites act independently.156
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Figure 4.2 (A) Lineweaver-Burk plots of the hydrolysis of 5h by -galactosidases (E. coli) in the
presence of 4b show competitive inhibition. (B) Cooperativity analysis of interaction of
galactonoamidines in the active sites of -galactosidases (E. coli) shows the independence of
active sites of the homotetramers.

After determining the galactonoamidines were competitive inhibitors that interact with only
one active site at a time, a SAR study was initiated using the library of 20 galactonoamidines. As
stated in the introduction, these galactonoamidines have aglycons with various interaction
capabilities.86 The SAR study revealed that the active site of -galactosidase (E. coli) supports
both hydrophobic and - interactions over the aglycon with a preference towards aglycons
imparting - interactions (Ki 4a < 4s), Table 4.1. The active site only supports cyclic aliphatic
aglycons for hydrophobic interactions; inhibitors with linear aliphatic do not bind as well within
the active site (Ki 4s< 4l). In ability of the active site to stabilize these linear aliphatic aglycons
decreases with the size of the aglycon (Ki 4l < 4m). This reduction in stability could be due in
part to the tightness of the active site and the proximity of loops of other monomers near the
active site interfering with proper binding.146 Nine inhibitors exhibited similar Ki (30-100pM)
and IC50 values (6.8-37nM), 4a-c, 4f-g, 4i-j, 4p, and 4s). Their tight binding led to the
consideration of them as possible TSAs for the hydrolysis of substrates by -galactosidase (E.
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coli). The inhibitors’ interactions within the active site were investigated further by molecular
docking and modeling studies.
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Table 4.1 Inhibition of hydrolysis of 4-nitrophenyl--D-galactopyranoside (kcat= 5478±107min-1and KM= 0.040±0.004mM) by galactosidase (E. coli) in the presence of galactonoamidines. 5mM HEPES buffer solution at pH 7.50±0.05 and 30.0±0.1°C. 56

Ki
[nM]

IC50
[nM]

Compound

Ki
[nM]

IC50
[nM]

4a

0.03±0.01

19

4k

0.25±0.02

35

4b

0.06±0.0156

9.8

4l

0.23±0.03

8.5

4c

0.09±0.01

25

4m

2.6±0.28

8000

4d

0.25±0.02

103

4n

0.15±0.02

244

4e

0.15±0.02

31

4o

0.12±0.01

15

4f

0.03±0.0

37

4p

0.10±0.01

31

4g

0.08±0.01

6.8

4q

1.30±0.14

62

Compound

R Group

R Group
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Table 4.1 Cont’d: Inhibition of hydrolysis of 4-nitrophenyl--D-galactopyranoside (kcat= 5478±107min-1and KM=
0.040±0.004mM) by -galactosidase (E. coli) in the presence of galactonoamidines. 5mM HEPES buffer solution at pH
7.50±0.05 and 30.0±0.1°C
Ki
IC50
Ki
IC50
Compound
R Group
Compound
R Group
[nM]
[nM]
[nM]
[nM]
4h

0.25±0.02

15

4r

0.25±0.04

37

4i

0.06±0.01

9.7

4s

0.09±0.01

9.4

4j

0.06±0.1

15

4t

0.11±0.01

24
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4.2.2 Molecular docking and modeling of galactonoamidines
Though crystallization of the galactonoamidines within the active site of -galactosidase
(E. coli) has been unsuccessful thus far, molecular docking and dynamics of the inhibitorenzyme complexes are possible. The nine inhibitors (4a-c, 4f-g, 4i-j, 4p, and 4s) with high
binding affinities and low IC50 values were further examined through docking and molecular
modeling analyses to determine the interactions occurring within the active sites. The
interactions observed through these analyses will be compared to the previously discussed
interactions known to occur with substrates. Based on previous studies, it is known that a TSA
should have interactions with both catalytic residues, and that orientation of the aglycon plays a
key role in TSA binding.79, 93 Therefore, the initial docking analyses focused on the hydrogen
bonding interactions with catalytic residues and the positioning of the galactonoamidines’
aglycon.
The attempts at docking the ligands with AutoDock Vina as performed with previous galactosidases from bovine liver and A. oryzae failed. The algorithms used for determining
docking conformations with AutoDock did not accurately model interactions occurring in the
active site of -galactosidase (E. coli) due to the two metal ions within the active site.
Previously, others revealed similar problems with Autodock Vina and enzymes with metal ions
within the active sites.157 They found that though Autodock Vina gives the most similar ligand
orientation to crystalized ligands, the software cannot give the exact orientations found in crystal
structures.157 Thus, the nine galactonoamidines were manually inserted into the active site and
overlain with the ligands that were crystallized within the active site. The interactions of the nine
inhibitors, along with a ligand representing a reaction intermediate (2a, Figure 4.3) and an
assumed TSA (3k), were further characterized by molecular dynamics. Since the interactions of
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2a and 3k have been determined through crystallization studies,146 the molecular dynamics
studies can be validated using these molecules. The inhibitor representing the reaction
intermediate, 2a, was found to have hydrogen binding interactions with His391, Asp201, His540,
and Asn604 through the crystallization studies.146 Whereas, the deep binding inhibitor, 3k, has
hydrogen bonds to His391, Asp201, His540, and Asn604 as well as Asn460, Glu461, and
Glu537 in the crystal structure.

Figure 4.3 Substrate, 2-fluoro-2-deoxy--D-galactopyranoside (2a), crystallized within the
active site of -galactosidase (E. coli), PDB ID 4V45.146
Protein inhibitor complexes were built with dimers rather than the tetrameric protein for
simplicity and examined with GROMOS96 43A1 force field using GROMACS over a 48ns
production phase. Initially, the hydrogen bonding interactions of 2a and 3k with residues in the
active site of -galactosidase (E. coli) were examined to ensure the model was accurate, Figure
4.5. Theses hydrogen bonds were characterized as either strong hydrogen bonding interactions or
week hydrogen bonding interactions based on the distance of acceptor to donor. Strong hydrogen
bonds of the complexes of inhibitors with proteins were classified as a bond were the acceptor
and donor were within 3.2Å of each other, which was cutoff used for determining hydrogen
bonds from the crystallization studies. 146 Weak hydrogen bonding interactions are those in
which the donor and acceptor are up to 3.5 Å apart. At first here was concern over some
interactions described in the crystal structures not being observed in the simulations. However,
we found that the probability of observing a hydrogen bonding interaction in the simulation
decreases as the distance of the hydrogen bonding interactions in the crystal structure increases.
All missing hydrogen bonding interactions in the simulations were ≥3.0Å from donor to acceptor
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in the crystal structure. When the weak hydrogen bonds are examined alongside the strong
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hydrogen bonds the interactions better match those observed in the crystal structures.

Figure 4.4 Hydrogen bonding interactions of 2a and 3k with -galactosidase (E. coli)
After establishing a similar interaction profile with the simulations and crystal structure of
the model compounds, the overall structure of the protein was examined to ensure that the
protein integrity was maintained through the simulations when using dimers rather than
tetramers. Though the hydrogen bond occupancy of 2a and 3k are low for the expected residues,
the active sites of -galactosidase (E. coli) does not fall apart, Figure 4.5. While there are small
shifts in the residues surrounding the active site during both simulations the overall structure of
the protein within 15Å of the active site remains the same as the crystal structure throughout the
simulations (RMSD of 1.13Å for 2a and 0.985Å for 3k), Figure 4.5.The low occupancy is most
likely due to the low binding affinity of these compounds to -galactosidase (E. coli) rather than
an error in the simulations. The inhibition constants of both 2a and 3k are in the M
concentration range, whereas the inhibition constants with galactonoamidines are in the pM
concentration range. Therefore, we would expect the hydrogen bonding occupancy of 2a and 3k
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with -galactosidase (E. coli) to be less than those of the galactonoamidines. The overall
conservation of hydrogen bonding interactions and protein structure between the crystal structure
and the molecular dynamics simulations validates this methodology.
A

B

C

D

Figure 4.5 A) Crystallized (purple) -galactosidase (E. coli) in complex with 2FG (yellow) and
the final coordinates of -galactosidase (E. coli) after 48ns of simulation (grey) within 15A of
the active site. B) Active site residues from the crystal structure (purple) and simulated galactosidase (grey) after 48ns with 2FG in yellow. C) Crystallized (red) -galactosidase (E.
coli) in complex with GTZ (blue) and the final coordinates of -galactosidase (E. coli) after 48ns
of simulation (grey) within 15A of the active site. D) Active site residues from the crystal
structure (red) and simulated -galactosidase (grey) after 48ns with GTZ shown in blue.
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After establishing the model for ligand interactions was correct we moved to examining the
interactions of the nine galactonoamdines within the active site of -galactosidase (E. coli). First,
the hydrogen bonding interactions with the galactonoamidines were examined, then the
orientation of the glycon within the active site, and finally the interactions of the aglycon. Since
the only interaction known to occur with the natural aglycon, glucose, is a stacking interaction
with Trp999, this will be the initial focus of the aglycon examinations.
Previous molecular dynamics simulations with TSAs in complex with other galactosidases showed that interaction with both catalytic residues within the active site are
crucial. Complexes with 4a-c, 4g and 4s all have a high probability of interaction with both
catalytic residues (Glu461 and Glu537), Figure 4.6A-C, E, and I. Complexes with 4f and 4j lack
of interaction with the proton donor, Glu461, and thus can be eliminated from further scrutiny
Figure 4.6 D and G. All of the inhibitors show a high probability of interaction with Asp201 and
the nucleophile Glu537. Further investigations of the glycon binding of the galactonoamidines
revealed that six galactonoamidines (4a, 4b, 4g, 4j, 4p, and 4s) stack on Trp568 similarly to
inhibitors observed through crystal structures (Figure 9.2), with the face of the glycon parallel to
the side chain of Trp568. The other three galactonoamidines, 4c, 4f, and 4i, are oriented so that
the glycon is perpendicular to the side chain of Trp568. The overall hydrogen bonding
interactions of 4p and the active site was significantly less that all other complexes, Figure 4.6
and Figure 9.1. Galactonoamidines 4c, 4f, 4i, 4j, and 4p were excluded from further scrutiny
based on the glycon interactions within the active site.
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Figure 4.6 Hydrogen bonding interactions of galactonoamidines 4a (A), 4b (B), 4c (C), 4f(D), 4g(E) and 4i(F) with -galactosidase
(E. coli)
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Figure 4.6 cont’d Hydrogen bonding interactions of galactonoamidines 4j (G), 4p (H), and 4s(I) with -galactosidase (E. coli)
A

B

Figure 4.7 Snap shot of the loop closure with complex of -galactosidase (E. coli) and 4a. Only protein within 10Å of 4a is shown for
clarity.
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As already stated the only knowledge about the binding of an aglycon within the active site
is the stacking that occurs between glucose and Trp999. Galactonoamidines 4a and 4b show -
stacking interactions with Trp999, 4s shows CH- interactions with the aglycon and Trp999, and
4p has hydrophobic interaction with Trp999, Figure 9.3. Galactonoamidine 4g on the other hand
shows interaction with the opposite wall of the active site (Glu281, Arg282, Glu416, Ser462,
Glu487, and Lys517). The fluoro-group of the aglycon is imbedded in this hydrophilic pocket of
residues that is not observed in any other complex. Along with Trp999, 4a, 4b and 4s have
hydrophobic interactions with Phe601, Phe512, Met502 and Val103. Complexes with 4a and 4b
show additional hydrophobic interactions with Pro511. The aglycon of 4a has further
interactions with Met423, while the aglycon of 4b has an additional interaction with Pro513.
Further, the galactonoamidines all showed movement of loop 794-803 towards the active
site, with complete movement of the loop over the active site for complexes with 4a, 4b, and 4s,
Figure 4.7. The other inhibitors only showed some movement of the loop towards the active site
not complete closure. Based on these molecular dynamics simulations galactonoamidines 4a, 4b,
and 4s were further evaluated spectroscopically as TSA
4.2.3 Spectroscopic evaluation of galactonoamidines as TSA.
The galactonoamidines’ inhibition of hydrolysis of nine nitrophenyl--D-galactopyranoside
(5a-k)70 by -galactosidase (E. coli) was examined through Bartlett method,78 Figure 4.8. As
stated in previous chapters, an inhibitor that is a TSA will result in a double-logarithmic plot
with a linear fit and correlation factor (R2) similar to 1. 54, 78 All eleven substrates were inhibited
in the low picomolar range by the three galactonoamidines (9.5-900pM), Table 4.2. The linear
fit of the data obtained from inhibition of substrate hydrolysis by 4a and 4b was near 1 and both
data sets had correlation factors near 1, Figure 4.9A. Though the linear fit of the data from 4s
67

gave a slope within error of 1, the correlation of the data was very poor (R2=0.61), Figure 4.9B.
The afore stated criteria qualified galactonoamidines 4a and 4b as TSAs, while excluding 4s.
With the two TSAs (4a and 4b) in hand, the inhibition ability of the TSAs and the opportunistic
inhibitor (4s) were examined in solution with multiple proteins. To our knowledge, the inhibition
of glycoside hydrolases by TSAs has been not by studied under such conditions.

Figure 4.8 Transition state of model substrates’ (5a-k) hydrolysis by -galactosidases (grey).70
Table 4.2 Galactonoamidine inhibition of hydrolysis of 11 nitrophenyl--D-galactopyranosides
by -galactosidase (E. coli); 5mM HEPES buffer solution at pH 7.50±0.05 and 30.0±0.1°C.

Entry
5a
5b
5c
5d
5e
5f
5g
5h
5i
5j
5k

kcat
[sec-1]
860±20
153±15
1,320±89
2,260±69
1,870±120
1,950±97
3,570±250
91±2
504±25
260±10
640±1500

KM
[mM]
0.15±0.008
0.08±0.003
0.25±0.003
0.18±0.05
0.11±0.012
0.42±0.030
1.66±0.40
0.04±0.004
0.12±0.009
0.04±0.005
0.06±0.009

Ki 4a
[pM]
42±5
94±8
36±3
17±3
9.5±0.8
49±4
75±3
33±5
36±4
40±1
13±2

Ki 4b
[pM]
87±9
233±40
141±2
51±3
36±5
181±1
213±7
60±8
118±25
90±7
42±1

Ki 4s
[pM]
151±50
350±70
155±23
145±15
16±4
247±21
603±15
86±4
900±10
46±5
92±3
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Figure 4.9 Double-logarithmic correlation of inverse catalytic efficiency (KM/kcat) and the
inhibition constant (Ki) with linear fit y = ax + b for the 9 nitrophenyl--D-galactopyranosides in
the presence of (A); 4a (navy circle) a = 0.99 ± 0.10, R2 = 0.92 and 4b (orange square) a = 0.91 ±
0.11, R2 = 0.91; (B) (4s) (purple pentagon) a = 1.15 ± 0.35, R2 = 0.61.

4.2.4 Inhibition of -galactosidase in cell assays
After examining the inhibitors as TSAs, focus turned to the ability of the inhibitors to
interact with the -galactosidase in cell assays. These inhibitors were selected to examine if a
TSA will have an increase the inhibitory ability of the galactonoamidines in the presence of other
proteins or if the opportunistic binders will bind just as well as seen in the SAR studies with the
commercially available enzyme. Initial efforts to investigate the interactions of
galactonoamidines within live cells failed. The increase of turbidity observed during the growth
of cells impeded efforts to quantify hydrolysis by UV/vis and fluorescence spectroscopy (data
not shown). This required lysing of the cells so the cell growth would not affect measurements of
product formation. Along these lines, we endeavored to determine the ability of
galactonoamidines to inhibit the hydrolysis of substrate by -galactosidase (E. coli) in lysed cells
and a crude protein extract from these cells. The turbidity of the lysed cell suspension and crude
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protein extract made UV/vis analysis of substrate cleavage impractical, so we turned to
evaluations of hydrolysis of 4-methylumbelliferyl -D-galactopyranoside (5m) as the model
substrate, Figure 4.10. The resulting product, 4-methylumbelliferone (6), is easily tracked by
fluorescence at an excitation wavelength of 365nm and emission wavelength of 460nm. The
turbidity of the lysed cell suspensions was much greater than the crude protein extract, which
made the data obtained inconclusive; therefore, we will not speculate to the inhibition of galactosidase in these suspensions.

Figure 4.10 Hydrolysis of model substrate, 4-methylumbelliferyl -D-galactopyranoside (5m).

Both the TSAs (4a and 4b) and opportunistic binder (4s) reduce the -galactosidase
activity in the crude protein extract at lower concentrations than commercial -galactosidase (E.
coli),Table 4.3. The galactonoamidine that reduces the activity of the crude protein extract and
the -galactosidase (E. coli) to the highest extent at lower concentrations is 4s, Figure 4.11C.
Though the 4s is only an opportunistic binder rather than a TSA it is able to inhibit the galactosidase activity to a greater extent. This shows that though the TSAs are better suited to
establish the interactions occurring within the active site at the transition state, they are not
always the most potent inhibitor for the enzyme. It is possible that the TSAs (4a and 4b) interact
with other glycosidases within the crude protein solution and thus more of the TSAs must be in
solution to inhibit the activity.
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Table 4.3 Inhibition of hydrolysis of 4-methylumberlliferyl--D-galactopyranoside (5m) by galactosidase (E. coli) in the presence of galactonoamidines. 5mM HEPES buffer solution at pH
7.50±0.05 and 37.0±0.1°C.
Commercial
-gal (E. coli)
IC50 [nM]
26.4±2.1
31.4±2.2
1.74±0.02

Crude Protein
Extract
IC50 [nM]
0.12±0.010
0.35±0.01
0.03±0.01

Inhibitor
4a
4b
4s
A

B
-galactosidase Activity [%]

-galactosiase Activity [%]

100
80
60
40
20
0
-6

-5

-4

-3 -2 -1
Log(I); [M]

0
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Figure 4.11 Activity of -galactosidase (E. coli) from crude protein extract (half squares) and
purified protein (half circles) in the presence of (A) 4a, (B) 4b, and (C) 4s.
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4.2.5 Purification of -galactosidase (E. coli)
The ability of the galactonoamidines to bind to the crude protein extract two orders of
magnitude more than the commercial protein was concerning. Thus, the -galactosidase from the
crude extract was purified to ensure it was catalytically similar to the commercial enzyme. The
purification was accomplished by the method established by Fowler and Zabin with the
modifications from Jacobson and Matthews.158, 159 Characterization of the purified protein was
achieved through circular dichroism, SDS-PAGE electrophoresis, and Gel permeation
chromatograph (GPC) analyses by comparison to the commercial -galactosidase.
GPC analysis of the purified and commercial -galactosidases resulted in very similar
retention times, Figure 4.12. Both protein solutions had trace peaks that were determined to be
insignificant compared to the -galactosidase (E. coli) peak. The structures of the commercial
and purified -galactosidase were compared using circular dichroism. These data were also
compared to a spectrum calculated using PDB2CD software.160 The calculation of CD spectrum
was to ensure that the spectra obtained matched the expected spectrum of the -galactosidase (E.
coli). The three spectra overlay nicely showing that there is not a misfolding or denaturation of
the proteins that would cause a difference in affinity for the model substrates, Figure 4.11.
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Figure 4.12 A) Comparison of commercial (red) and purified (blue) -galactosidases by GPC
analysis. B) Comparison of estimated  by PDB2CD (black) to the experimental CD obtained
with purified (blue) and commercial (red) -galactosidase (E. coli).160

4.2.6 Inhibition of purified (E. coli)
With the purified -galactosidase in hand, we set out to examine the ability of the
galactonoamidines to bind to the purified -galactosidase. The same three galactonoamidines
were used to test the inhibition on the purified -galactosidase compared to the commercial
enzyme: the two TSAs (4a and 4b) and the opportunistic binder (4s). The inhibition constants of
galactonoamidine inhibition of the two -galactosidases were very similar with an error of only
4% between the two, Table 4.4. Thus, the -galactosidase within the crude protein extract is not
binding the galactonoamidines more tightly on its own. Therefore, something about the crude
protein extract itself is causing the galactonoamidines to be bound more tightly in this solution.
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Table 4.4 Inhibition of hydrolysis of 4-nitrophenyl--D-galactopyranoside (5h) by galactosidase (E. coli) in the presence of galactonoamidines. 5mM HEPES buffer solution at pH
7.50±0.05 and 30.0±0.1°C.
Inhibitor

Commercial
-gal (E. coli)
Ki [pM]

Purified
-gal (E. coli)
Ki [pM]

4a
4b
4s

33±6
59±7
86±4

31±3
56±13
81±4

The ability of the inhibitors to inhibit the crude protein extract to such extent without the galactosidase within the extract being less active is impressive. This shows that the inhibitors
have the ability to bind the -galactosidase specifically when in a solution of various other
proteins. Given other methods of detection, it is highly probable that the galactonoamidines
would be able to inhibit -galactosidases within a cell.
Conclusions
The active site of -galactosidase from E. coli was probed with 20 galactonoamidines. As
expected, the library of galactonoamidines was able to inhibit the hydrolysis of substrate by galactosidase (E. coli) in the low picamolar concentration level (0.03-1.35nM). Initial SAR
studies with 20 galactonoamidines revealed nine galactonoamidines (4a-c, 4f-g, 4i-j, 4p, and 4s)
bound with similar IC50 values (6.8-37nM) and inhibition constants (30-100pM). Molecular
dynamics analyses revealed that six (4c, 4f-g, 4i-j, and 4p) of these inhibitors were unlikely to be
TSAs based on the binding within the active sites being different than substrates previously
crystallized within the active site. Spectroscopic evaluations of the three remaining inhibitors
(4a, 4b, and 4s) revealed 4a and 4b are TSAs of the hydrolysis of substrate by -galactosidase
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(E. coli). Though -galactosidase from E. coli is one of the most studied enzymes, no TSA had
been determined experimentally until now.
Evaluation of the inhibition of -galactosidase activity within a crude protein extract by
galactonoamidines revealed inhibition of the hydrolysis of model substrates two orders of
magnitude more than the purified -galactosidase. This increase in inhibition occurred with both
TSA and opportunistic binders, showing that though not all galactonoamidines are TSAs, they
are still some of the most potent inhibitors known.

Materials and Methods
4.4.1 Instrumentation:
CD spectra were obtained on a Jasco J-1500 CD spectrometer Model 150 with a EXOS
liquid cooling system from Koolance Inc.161 The supplied Spectra Manager software version
2.12.00 was employed for recording the spectra using a Thomas Scientific Quartz
Spectrophotometer cell with a 1mm path length at 37.00±0.01°C.161 An HPLC system from
Shimadzu with a CBM-10A communications bus module, an LC-20AD analytical pump, DGU20A3R three channel online degassing unit, a SIL-20A UFLC autosampler with 96 well
capability, a CTO-20A/prominence column oven, ELSD-90LT light scattering and LC solution
software (vers. 1.25) from Shimadzu for data collection and analysis was used to establish purity
of -galactosidase (E. coli).86 GPC analysis of protein purity was performed using a YarraTM
3uM SEC-3000 column (Phenomenex) at 40°C with nanopure water as the isocratic eluent with
a flow rate of 1.0L/min at 60°C. 86 All cell work was carried out in a Purifier Class II Biosafety
Cabinet (Labconco) using aseptic technique. All media and glassware used during propagation of
cells were autoclaved in a SG-1200 Steam sterilizer Autoclave (Steris Amsco Scientific). E. coli
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cells were incubated in a Innova 4330 Incubator Shaker (New Brunswick Scientific; 37.0 ±05
°C). Growth of cells was tracked at Optical Density 600nm (OD600) with an Agilent 8453
UV/Vis spectrometer with a tungsten lamp using a disposable semi-micro cuvette (1.5-3mL)
with a 10mm pathlength (BrandTech Scientific). The data were visualized with UV-Visible
Chem Station B.02.01 SP1 software. Cells were harvested using J2-HS Refrigerated Centrifuge
(Beckman Coulter) and Jouan CR412 refrigerated centrifuge (Scimetrics), only used for samples
less than 100mL. Cell lysis was carried out using a Digital Sonifier (Branson) with a tapered 1/8
inch micro tip. Lyophilization of lysed cell was performed using a Freezone 1 liter benchtop
freeze drying system (Labcono). Purification of -galactosidase (E. coli) was carried out on a
Biologic Low-Pressure Liquid Chromatography system (Bio Rad) equipped with a SV-5 Buffer
Select Valve, Gradient Mixer, and BioFrac Fraction Collector. A PowerPac HC electrophoresis
system (BioRad) with a Mini-Protean Tetra System chamber was used for electrophoresis
analysis of purified samples. A Galaxy 5D centrifuge (VWR) was used for concentrating protein
samples in Nanosep Centrifugal Devices (PALL Life Sciences) with an 10kDa molecular weight
cutoff. All other instrumentation was described in section 2.4.1.
4.4.2 Materials:
Commercial -galactosidase (E. coli) was obtained as a lyophilized powder from Sigma
Aldric and used as received.56 pST5832 was a gift from Carolyn Bertozzi & Jessica Seeliger
(Addgene plasmid # 36256).162 A 30kDa Microsept Advance centrifuge device (Pall
Corporation) was used to concentrate fractions from purification. DEAE Sephacel (GE Health
Sciences) and p-amino-benzyl-1-thio--D-galactopyranoside agarose (Sigma Aldrich) resins
were added to separate 1.5x30cm columns (Bio Rad) until a 20mL bed volume was obtained.
Isopropyl -D-thiogalactopyranoside (IPTG) was synthesized by Ifedi Orizu according to a
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general procedure described Fairbanks.163 Luria Berani media, ethylenediaminetetraacetic acid
(EDTA), Calcium chloride, ammonium sulfate, potassium chloride, and agar were purchased
from Sigma Aldrich as proteomic grade or higher. Kanamycin sulfate, TRIS buffer, Magnesium
chloride, UREA, Phenylmethyl sulfonyl fluoride, TEMED, and Sodium chloride were purchased
from VWR as proteomics grade or higher. Trichloroacetic acid (Beantown chemicals), Sodium
Dodecyl Sulfate (TCI), and -mercaptoethanol (Acros organics) at 99% purity were used as
received. All other materials have been described in section 3.4.2.
4.4.3 Spectroscopic evaluations of commercial enzyme.
Stock solution of inhibitors:
Typically, 0.00025, 0.0025, 0.005, 0.05, 0.125, 0.25, 0.5, 2.5, 10, 20, 30, 50 and 100mM
inhibitor solutions were prepared by diluting aliquots of 100M aqueous solution of the
galactonoamidines with nanopure water. All resulting inhibitor stock solutions were used in
10L aliquots in IC50 and Ki assays and kept at ambient temperature until pipetted into plates.
Stock solutions of inhibitors in concentrations of 0.025-0.2nM for 4a-c, 4e-j, 4l, 4n-p, and 4s-t
and 0.25-1.0nM for 4d, 4k, 4m, 4q-r, and 4u-v were used in the determination of Ki values.
Stock solution of substrate:
All substrate solutions were prepared immediately before use and kept at ambient
temperature until pipetted into the plates.56 Substrate solution was prepared by dissolving 4.616.93mg nitrophenyl--D-galactopyranoside (5a-k) in 20mL 5mM HEPES buffer solution (pH
7.50) in a volumetric flask and then diluted 1:1 with 5mM HEPES buffer solution (pH 7.50) for a
final 0.37-0.65mM substrate solution.56
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Stock solution of commercial enzyme:
A 5mg sample of -galactosidase (E. coli) was dissolved in 1mL of degassed nanopure
water.56 The sample was aliquoted into 10L samples and stored at -80°C until use.56 A BCA of
the aliquoted samples revealed a concentration of 33.13±1.62M.56 Prior to use, a single sample
was thawed and diluted to 5mL in a volumetric flask with 5mM HEPES buffer solution (pH 7.50
at 30°C).56 Then, an 80L aliquot of the solution was diluted to 10mL with the buffer solution in
a volumetric flask.56 The final monomeric concentration was determined to be 528±26pM.56 The
stock solution was kept on ice until use in 20L aliquots.56
Kinetic Assay with commercial enzyme:
The kinetic assay was performed as described in section 2.4.3.5 with the following
changes: The plate was then read at a wavelength of 405nm at 30°C for 30 min every 27s.56
Data analysis:
The data analysis for kinetic evaluations was described in section 2.4.3.6.
4.4.4 Inhibitor cooperativity analysis:
4b was selected as a model galactonoamidine to show only a single class of inhibition sites
was available to the galactonoamidine. For class of inhibition analysis, the four apparent KMs
were plotted versus the concentration of galactonoamidine.164 A linear regression was performed
on the data; the R2 was then examined to determine the linearity of the data. If the linear
regression shows a high linearity, R2, the inhibitor is only acting on a single class of active
sites.164
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4.4.5 Molecular docking and modeling of protein inhibitor complexes
The PDB coordinates of -galactosidase (E. coli) in complex with 2-flouro-2-deoxy--dgalactopyranoside (4V45) and galactotetrazole (1JZ6) were obtained from the Protein Data
Bank. The water molecules were removed from the PDB coordinates and used without further
modification in the case of these two control compounds. However, for all galactonoamidines
complexes, the inhibitors were manually inserted in the active site of the b-galactosidase and
overlain with the crystallized inhibitors. After obtaining the coordinates for the overlain
galactonoamidines the inhibitors were removed from the active site along with all water
molecules.
Protein inhibitor complexes were built with dimers rather than the tetrameric protein for
simplicity using the GROMOS96-43A1 force field with GROMACS 4.6.7 software. The dimeric
PDB coordinates were converted to a GROMACS coordinate and topology files by employing
the pdb2gmx program. The pdb coordinate files for all inhibitors were converted to GROMACS
coordinate files by the free software PRODRG. The chirality of all inhibitors was maintained and
all partial charges were defined as GROMOS96-43A1 forces field without further energy
minimization by PRODRG. The inhibitor topology files were corrected by reducing all charge
groups to 3-4 atoms and correcting all partial charges with guidance from a recent study by
Lemkul et al. 1
The edited topology and coordinate files of the inhibitors were appended to the dimeric bgalactosidases to create protein-inhibitor complexes. The protein inhibitor complexes were
centered in a 8304.76nm3 cubic box and solvated with 266,740-266,754 simple point charge
water molecules and neutralized with 64 sodium ions. The systems were equilibrated as
previously described and a 48ns NPT simulation was used as production phase.2, 3 The hydrogen
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bonding interactions of inhibitors were determined using the H-bond plugin in the Visual
Molecular Dynamics (VMD) program. Strong hydrogen bonds of the complexes of inhibitors
with proteins were classified as a bond were the acceptor and donor were within 3.2Å of each
other, which was cutoff used for determining hydrogen bonds from crystallization. 4 Weak
hydrogen bonding interactions are those in which the donor and acceptor are up to 3.5 Å apart.
4.4.6 Propagation of E. coli cells for cell assays
The E. coli (strain K12) cells containing a pST5832 plasmid were purchased from
Addgene.162 A sterile inoculation loop was used to spread the purchased bacteria over a LuriaBertani Agar plate with 30g/mL Kanamycin antibiotic in the plate. The plate was incubated for
20 hours at 37°C. Then, five colonies were selected from the plate and placed in 10mL of sterile
LB broth with 30g/mL Kanamycin. This culture was incubated in an Innova incubator shaker
for 16 hours. A 3.3mL aliquot of 50% sterile glycerol solution was added to the 10mL culture
and the culture was stored in 500L aliquots at -80°C until use.
Cells were grown in Luria-Bertani (LB) broth at 37.5°C. Growth of cells was monitored
spectrophotometrically at a wavelength of 600nm (OD600).158 Cells grown from 2L cultures were
harvested when the logarithmic growth reached an optical density (OD600) of 2.5-3.0.166 Cells
were harvested at 6,000rpm and 4°C for 20min. The supernatant was discarded and the cell
pellets were re-suspended in 60mL of 5mM HEPES buffer solution. The re-suspended pellets
were combined into two pre-chilled High performance VWR centrifuge tubes. The re-suspended
cell pellets were then centrifuged at 6,000rpm, 4°C for 15 minutes. The supernatant was
discarded and the final cell pellets were stored at -20°C until processed for further use. The cell
pellets were processed two ways for the cell assays: lysed cells and a crude protein extract from
cells.
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4.4.6.1 Lysed E. coli cells:
Two of the 5mL cell pellets were thawed and each was suspended in 10mL of buffer
solution. The cells were then lysed while suspended in an ice bath using a Branson digital
sonicator for 5 minutes at an amplitude of 40%. The sonication was performed with 5sec on
followed by 5sec off. After the sonication, the cells were allowed to rest in ice for 5 minutes.
Then the sonication and rest cycle was repeated twice for a total of 15 minutes of sonication and
15 minutes of rest. The resulting suspension was then flash frozen with liquid nitrogen and then
freeze dried on over 72 hours. A total of 1.3198g lysed E. coli cells was obtained.
4.4.6.2 Crude protein extract from E. coli cells:
Two cell pellets obtained from an expression of E. coli cells were thawed and each were resuspended in 15mL of the above 5mM HEPES buffer. The cell suspension was sonicated as
explained above in section 4.4.6.1. The resulting suspension was then transferred to a 50mL
VWR High performance centrifuge tube and centrifuged at 19,000rpm and 4°C for 25 minutes.
The supernatant containing the crude protein extract was collected (total of 21mL) and aliquoted
out into microvials (1mL aliquots). The aliquots were flash frozen with liquid nitrogen and
stored at -80°C until further use.
4.4.7 Purification of -galactosidase (E. coli)
4.4.7.1 Propagation of cells:
A vial of 500L E. coli cells containing the pST5832 plasmid was thawed and pipetted into
5mL of sterile LB broth.162 The culture was incubated at 250rpm at 37°C for 6 hours; then a 1mL
aliquot of this solution was used to inoculate a 100mL sterile LB broth in a 1L flask. The culture
solution was shaken at 250rpm at 37°C for 15 hours in a Innova 4330 incubator shaker. After the
incubation time, 25mL of the culture was used to inoculate four Erlenmeyer flasks with 500mL
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of sterile LB broth, then incubated at 37°C and shaken at 250rpm until the desired optical density
(OD 0.4-0.6A.U.) was obtained. The total incubation time until OD600 of 0.53AU was reached
was 1hr after inoculation.
After the desired OD600 was reached, 1M isopropyl -D-1-thiogalactopyranoside (IPTG)
was added in 500L aliquots into each of the 500mL cultures. The cultures were incubated for
four hours after the addition of IPTG. Following the four-hour expression, the culture was
centrifuged for 15minutes at 6,000rpm, 4°C to harvest the cells. The supernatant was discarded
and the cell pellets were re-suspended in 30mL of 40mM Tris/0.5mM EDTA/10mM
MgCl2/5mM -mercaptoethanol buffer solution (pH 7.50). Then, the re-suspended pellets cells
were then centrifuged at 6,000rpm, 4°C for 15 minutes in a VWR High Performance centrifuge
tube. The supernatant was discarded and the resulting cell pellet was stored at -20°C until use,
each expression resulted in two large cell pellets.
4.4.7.2 Purification of -galactosidase (E. coli):
The two cell pellets obtained from an expression of E. coli cells were thawed and each
were re-suspended in 15mL of the above 5mM HEPES buffer. The cell suspension was sonicated
as explained above in section 4.4.6.1. The resulting suspension was then transferred to a 50mL
VWR High performance centrifuge tube and centrifuged at 19,000rpm and 4°C for 25 minutes.
Ammonium sulfate (typically 11.71g) was slowly added to the supernatant (50mL) over 30
minutes until 40% saturation.158 The suspension was stirred over two hours at 4°C then
centrifuged at 19,000rpm for 30 minutes to obtain the protein as a precipitate. The precipitate
was dissolved in 20mL 40mM Tris/0.5mM EDTA/10mM MgCl2/5mM -mercaptoethanol buffer
solution (pH 7.50) and placed in a 15kDa molecular weight cutoff dialysis bag.158 The crude
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protein suspension was dialyzed against the same buffer solution over 24 hours with a total of six
buffer exchanges.
After dialysis, the suspension was concentrated to 10mL in a 30kDa Microsept Advance
centrifuge device (Pall corporation) and applied to a column (1.5x30cm) of DEAE Sephacel (GE
Health sciences) that had been equilibrated with the 40mM Tris/0.5mM EDTA/10mM
MgCl2/5mM -mercaptoethanol buffer solution (pH 7.50).158 The column was washed with
buffer solution until all non-bound proteins had eluted, typically 240mL. Then, the column was
washed with the buffer solution with a linear gradient of aqueous 100mM-400mM NaCl solution
applied from a 2M NaCl stock solution.158 All fractions containing -galactosidase activity and
bands observed in by SDS-PAGE gels, typically from fractions containing 300mM and 400mM
NaCl, were pooled and concentrated down to 10mL.
The pooled solution was loaded onto a column of p-amino-benzyl-1-thio--Dgalactopyranoside agarose that had been equilibrated with 40mM Tris/0.5mM EDTA/10mM
MgCl2/5mM -mercaptoethanol buffer solution (pH 7.50) with 250mM aqueous KCl solution.159
After washing with this buffer solution, the buffer was switched to a 200mM Tris/0.5mM
EDTA/10mM MgCl2/10mM -mercaptoethanol buffer solution (pH 8.50) with 250mM aqueous
KCl solution.159 Protein was eluted from the column using a linear gradient of aqueous 0.25M1.5M KCl solution.159 Pure -galactosidase was obtained from fractions containing 0.5-1.0M
KCl.
4.4.7.3 Characterization of purified -galactosidase (E. coli):
Circular Dichroism
A 50L aliquot of the concentrated purified protein was added to 950L of nanopure water
and mixed. A 400L aliquot of this solution was then added to the spectrophotometer cell. The
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solutions were equilibrated to 37°C then analyzed. Measurements were performed between 190
and 250mm with a CD scale of 200 mdeg/1.0dOD, a data pitch of 0.1nm, a 20nm/min scanning
speed, and a 0.5nm band width. A total of three accumulations were obtained and averaged for
each sample by the software. Similarly, a 400L aliquot of a solution of 50L 5mM HEPES
buffer solution mixed with 950L of nanopure water was analyzed for a baseline.
Data analysis:
The cd [mdeg] of the baseline solution was subtracted from the cd [mdeg] of the protein
solution’s spectrum.161 The data were smoothed using a Savitzky-Golay smoothing with 5-points
to each side of the data with 5 iterations of smoothing.161 Then, the following equations were
used to determine the molar elipticity of the -galactosidase sample.161
Equiation I: [𝜃] =

[100∗𝜃]
[C∗𝑙]

Equation II: ∆𝜀 = [𝜃]/3298.2
An estimation of CD spectra for -galactosidase (E. coli) was obtained using PDB2CD by
uploading a pdb file (1JZ7) to the server.160 The obtained spectra were then overlaid with the cd
spectra obtained with the purified protein.
4.4.7.4 Gel permeation chromatography
Stock solutions of enzymes
Both solutions of -galactosidase (E. coli) were thawed and used immediately.
Stock solution of purified -galactosidase (E. coli): A 500L aliquot of purified protein was
concentrated to a volume of 150L using a 10kDa Nanosept concentration device (Pall).
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Stock solution of purchased -galactosidase (E. coli): A 100L aliquot of the working solution
of purchased -galactosidase was concentrated to 50L of protein using a 10kDa Nanosept
concentration device (Pall).
Assay
The sample was added to a Greiner BioOne 96 well microplate with conical well in 20L
aliquots. The samples were injected, in 5L aliquots, onto a YarraTM 3uM SEC-3000 column at
40°C (Phenomenex) with nanopure water as solvent using a Shimazu UFLC instrument. A
SEDEX 90 SEDERE LT-ELD detector was employed to determine retention times of samples.
Data analysis
The retention times ofeach sample were plotted against the intensity observed.
4.4.8 Spectroscopic analysis with lysed cells, crude protein extract, and purified protein.
Stock solution of crude protein extract: Typically, a 1mL aliquot of crude protein extract was
thawed and diluted to 5mL with 5mM HEPES buffer solution (pH 7.50 at 37°C) in a volumetric
flask. The concentration of total protein was determined to be 3.23±0.17mg/mL by BCA assay.
Stock solution of purified -galactosidase from E. coli: A 1000L aliquot of purified protein was
diluted to 5mL with 5mM HEPES buffer solution (pH 7.50 at 37°C) in a volumetric flask. A
BCA assay of the stock solution revealed a concentration of 81.6±6.8nM.
Stock solution of substrates: Stock solutions were prepared immediately before use and were
discarded if not used within four hours after preparation.
Stock solution for crude protein extract: 6.48-6.52mg (0.0192-0.0193mmol) 5m were dissolved
in 500L of DMSO, then brought to 10mL with 5mM HEPES buffer solution (pH 7.50 at 37°C)
in a volumetric flask (1.92-1.93mM).
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Stock solution for purified protein: 6.67-6.71mg (0.0191-0.0191mmol) 5m were dissolved in
500L of DMSO, then brought to 5mL with 5mM HEPES buffer solution (pH 7.50 at 37°C) in a
volumetric flask (3.94-3.97mM). A 1000mL aliquot of this solution was then diluted to 5mL
with 5mM HEPES buffer solution (pH 7.50 at 37°C) in a volumetric flask (0.790-0.793mM)
4.4.9 Assay to determine -galactosidase activity
A 10μL aliquot of stock solution of inhibitor was added into a well in increasing
concentration. In the twelfth well of the row, a 10μL aliquot of buffer solution was substituted
for inhibitor for an uninhibited hydrolysis. Substrate solution was then added to each well in
30μL aliquots. Then 40μL aliquots of 5mM HEPES buffer solution (pH 7.50 at 37°C) were
added to each well. Lastly, the stock solution of protein solution was added to each well in 20μL
aliquots. After 30 minutes, a 60s medium orbital shake was performed then the fluorescence was
read at an excitation wavelength of 360nm and an emission wavelength of 465nm for 24 hours
with a read every hour. Assays with the purified protein were shortened to 2.5 hours with a read
every 15 minutes due to the reaction completion being reached quicker.
Data analysis:
The appearance of product, 4-methylumbelliferone (6), was observed by fluorescence at
an excitation wavelength of 360nm and an emission wavelength of 465nm. The fluorescence of
inhibited hydrolysis were divided by the fluorescence in absence of inhibitor and transformed
into percentage to determine the percentage inhibition of each inhibitor. The percent inhibition
was then plotted as a function of the logarithmic concentration for each inhibitor. The IC50 was
determined by the concentration at which the enzyme was inhibited 50% by the inhibitor in the
duplicate experiments and then averaged for the final value.
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4.4.10 Assay to determine inhibition constants with purified -galactosidase
Stock solution of substrate: Typically, 6.37mg (0.0211mmol) of 4-nitrophenyl -Dgalactopyranoside (5h) was dissolved with 5mM HEPES buffer solution (pH 7.50 at 37°C), then
diluted to 5mL with the same buffer solution in a volumetric flask (4.23mM). Finally, a 1000mL
aliquot was diluted to 5mL with 5mM HEPES buffer solution (pH 7.50 at 37°C) in a volumetric
flask (0.846mM).
Assay conditions and data analysis was performed the same as sections 3.4.3.4 and 3.4.3.5.
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5

Conclusions and Outlooks
Glycoside hydrolases are able to stabilize the transition state for hydrolysis of substrates

within their active sites to accelerate the hydrolysis 1017 over that of non-enzymatic
hydrolysis.167 Establishing the interactions that occur over the transition state (TS) is difficult due
to its fleeting nature.67 Therefore, the interactions with transition state analogs (TSAs) are
examined instead.168-170 Many inhibitors had previously been designed as TSAs for glycoside
hydrolases; however, experimental evidence of true TSAs only existed for xyloside based
inhibitors and gluco- and manno-tetrazole based inhibitors.54, 69
Here we have examined the abilities of a library of 25 galactonoamidines to mimic the TS
of three -galactosidases: from A. oryzae,79 bovine liver, and E. coli. An initial structure activity
relationship (SAR) screening of the galactonoamidines established the predominate interactions
occurring within the active site of the glycoside hydrolases.86, 90 The predominate interactions
with the galactonoamidines depend on the origin of the -galactosidase.86, 90 The interactions
over the aglycon were diverse depending on source: the -galactosidase (A. oryzae) favored
hydrophobic interactions,79, 86 -galactosidase (bovine liver) favored - and CH-
interactions,90 while -galactosidase (E. coli) had all three interaction types. After narrowing
down the inhibitors with the highest binding affinities to the enzyme, spectroscopic evaluation of
the hydrolysis of 9-11 nitrophenyl--D-galactopyranosides revealed a single galactonoamidine,
4b, was a TSA for all three enzymes.79, 90
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Figure 5.1: Structure of the galactonoamidine (4b) that determined to be a TSA of the three
examined -galactosidases.

Molecular docking and modeling analysis revealed that 4b is stabilized by a synergy of
interactions in the enzymes which include hydrogen bonding, hydrophobic interactions, - and
CH- interactions, and conformational changes at the active site.79, 90 The conformational shift in

-galactosidases from bovine liver and E. coli resulted in a loop closure over the active site.90
This along with the synergy of other interactions resulted in an increased binding affinity of two
orders of magnitude compared to the -galactosidase from A. oryzae.90 These conformational
shifts when a TSA is bound in the active site occur through the beta/alpha loops at the entrance
of the active sites. Since all clan A glycoside hydrolases have the same TIM motif as their
catalytic site it is only logical that these beta/alpha loops play a part in stabilizing the transition
state of the glycoside hydrolases in this clan.
Further examination of these loops is needed to determine how the conformational shifts
are mediated and which residues play the largest role in stabilization. Most mutations of
glycoside hydrolase enzymes have been in attempts to establish interactions that occur over the
glycon during hydrolysis of substrates, while little to no mutations have been performed on
residues that interact with the aglycon. Mutations to these residues would show which
interactions are the most crucial to stabilizing the transition state of these enzymes and thus
allow for such a large increase in hydrolysis compared to non-enzymatic reactions.
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Appendix 1: Supplemental Information from Chapter 2
Molecular docking analysis with -galactosidase (A. oryzae)

Table 7.1 Hydrogen bonding interactions of the galactonoamidines (4b, 4l, 4n-o, and 4r-t) and
amino acid residues in the active site of -galactosidase (A. oryzae). From Section 2.2.1

Interacting partners
C2 OH
Glu142
Glu200
C3 OH
Glu298
C4 OH
Ala141
Tyr342
C6 OH
Asn199
Glu298
Endo NH
Glu200
Exo NH
Glu200

4b

4l

2.1Å
2.2Å

4o

4t

4s

4n

4r

2.1Å

2.2Å

2.2Å

2.4Å

2.4Å

2.1Å

2.1Å

2.3Å
2.2Å

2.5Å
2.6Å

2.4Å

2.3Å
2.1Å

2.5Å

2.6Å
2.5Å

2.6Å

2.2Å
2.5Å

2.2Å

1.9Å
2.0Å

1.1Å

1.9Å
1.9Å

1.9Å
2.7Å

2.0Å

2.0Å

2.8Å

2.3Å

1.9Å

2.3Å

2.5Å

2.7Å

2.8Å

2.6Å

1.9Å
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Appendix 2: Supplemental Information from Chapter 3
Determination of molar absorptivity of nitrophenylates.

8.1.1 Stock solution of phenols:
For phenol solutions, 3.14mg-5.79mg of the phenol were dissolved in 25mL 5mM HEPES
buffer solution at pH 7.50 (0.82-1.47mM). The phenol solutions were kept at ambient temperature
until pipetted into microplates.
8.1.2 Molar absorptivity Assay:
The stock solutions of phenols were pipetted in 10-70L aliquots into a 96-well plate, then
brought to 100L with 5mM HEPES buffer solution.70 The solutions were thermostated at 30°C
for thirty minutes then a low orbital shake was performed within the plate reader.70 The absorbance
was then read at a wavelength of 405nm as an endpoint read. 70
8.1.3 Data analysis:
The absorbances of the phenol solutions were plotted against concentrations of phenol
solution. 70 The linear regression obtained by this plot gave the extinction coefficient, 405,
multiplied by the pathlength of the 96-well microplate containing 100L of phenol solution in
5mM HEPES buffer solution at pH 7.50 and 30°C. 70 These apparent extinction coefficients were
then averaged for the three impartial concentrations of the phenol. 70 From these data, the molar
extinction coefficients were calculated based on path length described by the manufacture and
correcting for the volume within each cell. 70
Molar extinction coefficients for phenolates produced by the hydrolysis of model substrates
were determined at pH 7.50 and 30ºC in 5mM HEPES buffer 5a 405: 2871 M-1cm-1, 5b 405: 943
M-1cm-1 5c 405: 2964 M-1cm-1, 5d 405: 1674 M-1cm-1, 5e 405: 1590 M-1cm-1, 5f 405: 4499 M-1cm-
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1

, 5g 405: 780 M-1cm-1, 5h 405: 13300 M-1cm-1, 5i 405: 14400 M-1cm-1and, 5j 405: 15700 M-1cmand 5k 40514100 M-1cm-1
Molecular Dynamics snapshots of FQ248 in complex with b-galactosidase (bovine liver)

A

B

C

Figure 8.1 Snap shots of from the 30 ns simulation of the 4o (red) and -galactosidase (bovine
liver) complex showing the active site (A) before, (B) during, and (C) after the loop closure
event. The catalytic residues are shown in green and TRP272 and TYR484 are shown in
magenta.
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Appendix 3: Supplemental information for Chapter 4
Molecular Dynamics Simulations

9.1.1

RMSD Plots of b-galactosidase (E. coli) in complex with galactonoamidines:
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RMSD of the backbone of a dimer of -galactosidase (E. coli) in complex with (A ) 2FG and GTZ, (B) RK217, RK221, and FQ162,
(C) FQ065 and RK203, (D) FQ187 and RK222, and (E) FQ202 and FQ245 over the relaxation phase (35 to 48ns) and the RMSD from
the entire production phase (0 to 48ns) as an insert in each image.

9.1.2 Hydrogen bond Formation

Probability of Hbond Formation
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Figure 9.1 Frequency of hydrogen bonding interactions in correlation to the number of hydrogen
bonding of galactonoamidines with -galactosidase (E. coli).
9.1.3 Images

Figure 9.2 Snap shots of 2a and 3k within the active site of b-galactosidase (E. coli). Catalytic
residues are shown as green sticks, Trp999 and Trp568 are shown as cyan sticks, and the metal
ions are shown as spheres (cyan = Mg2+ and yellow= Na+)
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A
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Figure 9.3 Snap shots of the galactonoamidines within the active site of b-galactosidase (E.
coli). Green sticks are catalytic residues, cyan sticks are Trp999 and Trp568, and the metal ions
are shown as spheres (cyan = Mg2+ and yellow= Na+). (A) 4a, (B) 4b, (C) 4c, (D) 4f, (E) 4g, (F)
4j, (G) 4i, (H) 4p, and (I) 4s.
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SDS-PAGE

Figure 9.4 SDS PAGE analysis of fractions from the ion exchange column, DEAE Sephacel.
The fractions containing -galactosidase (E. coli) were from the 300mM and 400mM NaCl
buffer solutions.

Figure 9.5 SDS PAGE analysis of fractions from the affinity column, p-aminobenzyl-1-thio-bD-galactopyranoside agarose. Pure -galactosidase (E. coli) eluted in fractions 19-25. Since
fraction 21 contained some contamination it was not pooled with the other fractions for the final
stock solution.
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Figure 9.6 SDS PAGE comparison of purified -galactosidase (E. coli) and the commercial galactosidase (E. coli).
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Figure 9.7 Activity of -galactosidase (E. coli) from (A) lysed cells, (B) crude protein extract,
and (A) purified protein in the presence of 4a (navy circle), 4b (orange square), 4i (grey
diamond) 4n (green triangle), and 4s (purple pentagon).
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